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Abstract 
 
G protein-coupled receptors (GPCR) constitute one of the largest family of transmembrane 
proteins that have been implicated in a multitude of diseases, including cancer and diabetes, and 
have been an important target in drug deve lopment. While experiment-based high-throughput 
screening for the unearthing of novel chemical compounds remains the de facto standard for drug 
discovery, virtual screening has been gaining acceptance as an important complementary method 
due to its high speed and low cost, which instead employs computers.  
 
This dissertation is aimed at the development of virtual screening algorithms as applied to GPCR’s, 
in addition to the construction of GPCR-related databases (GPCR-EXP, GLASS). MAGELLAN 
is a ligand-based virtual screening algorithm that makes inferences about what a GPCR would 
potentially bind based on sequence- and structure-based alignments. Building on top of this work, 
a sequential virtual screening pipeline combining MAGELLAN with AutoDock Vina was 
constructed for the discovery of novel, bifunctional opioids with mu opioid receptor (MOR) 
agonist and delta opioid receptor (DOR) antagonist activity.  
 
In the process of developing the virtual screening algorithms, two GPCR-related databases were 
constructed to provide necessary data for the study. GPCR-EXP is a database of experimentally-
validated and predicted GPCR structures. Important features include semi-manual curation of data, 
weekly updates, a user-friendly web interface, and high-resolution structure models with GPCR-
I-TASSER, which many of the other GPCR-related databases lack. Additionally, GLASS database 
was developed in response to the absence of databases dedicated to GPCR experimental data. As 
a result, pharmacological data was pooled and integrated into a single source, resulting in over 
500,000 unique GPCR-ligand associations; this made it the most comprehensive database of its 
kind thus far, providing the community with an accessible web interface, freely-available data, and 
ligands ready for docking.  
 
xv 
 
MAGELLAN utilized pharmacological data from GLASS to infer from the ligands of sequence- 
and structure-based homologues what a target GPCR would bind. It was tested on two public 
virtual screening databases (DUD-E and GPCR-Bench) and achieved an average EF of 9.75 and 
13.70, respectively, which compared favorably with AutoDock Vina (1.48/3.16), DOCK 6 
(2.12/3.47), and PoLi (2.2). Lastly, case studies with the mu opioid and motilin receptors 
demonstrated its applicability to virtual screening in general, as well as GPCR de-orphanization. 
Subsequently, MAGELLAN was combined with AutoDock Vina into a novel, sequential virtual 
screen pipeline against both MOR and DOR to compensate for the weaknesses of each algorithm. 
Retrospective virtual screens against both MAGELLAN and AutoDock Vina were established for 
both receptors, and both methods were reported to have over-random discrimination between 
actives and decoys using the GPCR-Bench dataset.  
 
In conclusion, structure (GPCR-EXP) and pharmacological data (GLASS) databases were 
constructed to provide users with a comprehensive source of GPCR data. Moreover, GLASS made 
it possible for MAGELLAN to be developed, providing it a rich source of experimental data. In 
return, this resulted in greater performance than competing algorithms. Lastly, a prospective 
sequential virtual screening pipeline was established for the discovery of novel bifunctional 
opioids, in which the models for both methods were validated to perform well. In future studies, 
cAMP and β-arrestin assays will be run on a subset of compounds from a prospective virtual screen 
in the hopes of discovering a novel opioid with reduced tolerance and withdrawal.  
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CHAPTER 1.  
Introduction to Chemoinformatics and Bioinformatics 
 
1. Brief Overview 
In research today, the modern scientist will likely at some point of their career encounter chemical 
or biological problems when manual analysis of their data is impractical due to its large size.  
Situations such as these require the usage of computational methods in order to make it possible 
to sift through data. However, this has typically required some knowledge of programming in the 
past, which can unfortunately be a steep learning curve. Fortunately, many web servers are 
available nowadays to provide an accessible interface to an algorithm of interest for the scientist 
lacking experience in computational methods. As a result, computational methods for life science 
have seen an explosion in usage in the scientific community 
 
Chemoinformatics is the application of computers in solving chemical problems, where a major 
application is in the in silico design of drugs. Within this field, cheminformatics is a specialized 
discipline that aims for efficiently working with enormous amounts of chemical data. For example, 
chemical similarity can be calculated between a reference compound and a virtual compound 
library in order to very quickly find chemically-similar compounds, as opposed to manually 
checking by eye.  Whereas cheminformatics works with chemical data, bioinformatics was 
developed to address biological problems on a large scale. For example, the alignment of DNA or 
protein sequences have historically been done manually, but with the introduction of sequence 
alignment algorithms decades ago, a reference sequence can be aligned with a database of 
sequences in a blink of an eye.  
 
Throughout this chapter, I will cover various aspects of chemoinformatics and bioinformatics, 
including computer representations of chemical compounds and proteins, chemical and biological 
databases, general bioinformatics, and virtual screening. Focus will be spent on concepts used in 
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the following chapters. Additionally, background information for G protein-coupled receptors 
(GPCR) will be presented. Finally, I will end with a segue into their role in my dissertation.  
 
 
2. Computer Representation of Chemical Compounds and Proteins 
Chemical compounds and proteins can be represented by a computer in a multitude of ways. Some 
formats are highly descriptive (i.e. PDB file format), while others are abstracted for fast 
calculations (i.e. molecular fingerprints). There are a dizzyingly large number of formats available, 
many frustratingly developed for proprietary purposes by companies, adding to the increasing lack 
of a standard. In this section, I will describe all of those used within this dissertation.  
 
2.1 PDB File Format 
Most researchers in biochemistry will be fairly acquainted with the PDB file format, since it has 
been primarily used to describe the three-dimensional structure of proteins, DNA, and RNA. This 
file format was first conceived in 1976 as a means to help researchers exchange protein coordinates 
through a database.1 Not surprisingly, its format has been revised and updated numerous times 
over the years. Essentially, a PDB file is a text file that contains various information about the 
Figure 1.1 – Representative Portion of PDB File. The portions with the ‘Record Name’ of ATOM helps software 
understand the identity and location of atoms and therefore help correctly process relevant information from the file. The 
amino acids, Glycine (GLY) in position 85 and asparagine (ASN) in position 86, from this structure are shown. 
3 
 
structure provided in specified ranges of columns. The file contains a variety of data, ranging from 
resolution and method used to solved structure to atomic coordinate specifications.  
 
One of the most important pieces of information within the PDB file is the ‘ATOM’ record name. 
An example is shown in Figure 1.1 that depicts the coordinates for two representative amino acids 
from a PDB structure. Each line depicts a single atom in the structure. For example, the first line 
corresponds to the backbone nitrogen of Gly-85. Furthermore, the atomic coordinates of this atom 
(-2.211, 29.344, -42.463) are given so that whichever algorithm or molecular visualization 
software is used can correctly process this representation.  
 
2.2 Line Notation 
Line notation allows for the representation of a chemical compound using a string of ASCII 
characters. Despite looking rather odd to the untrained eye, they are completely human readable, 
and someone familiar with the format would be able to interconvert between it and the 
corresponding 2D chemical structure. Nowadays, these are primarily used for chemical database 
searching. The Simplified Molecular-Input Line-Entry System (SMILES) and International 
Chemical Identifier (InChI) formats are currently the most widely used.  
 
SMILES strings were initially conceived in the 1980s as a means to make chemical compounds 
machine readable. Figure 1.2 shows the typical format of a SMILES string. Each letter represents 
an organic atom (B, C, N, O, P, S, F, Cl, Br, or I), and aromaticity is denoted with alternating equal 
signs (i.e. pyridine moiety: C4=CC=CC=N4). Additionally, rings are classified by including an 
opening and closing number (i.e. thiophene moiety: C1=C(SC=C1)). Single bonds are usually 
implicit, while double and triple bonds are represented as ‘=’ and ‘#’, respectively. The use of 
parentheses indicates branching, and stereochemistry is specified at chiral centers with ‘@’. 
SMiles ARbitrary Target Specification (SMARTS) strings were developed by the Daylight 
Chemical Information Systems as a robust extension of the SMILES string that provided expanded 
functionality, such as the ability to filter a compound database by substructure. However, one of 
the biggest drawbacks of this format is that there is no standard way in which to generate the 
SMILES string.2 This can complicate database searching, especially when a compound of interest 
cannot be found due to this problem.  
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InChI strings were developed in 2005 by the International Union of Pure and Applied Chemistry 
(IUPAC) in response to the inconsistencies produced by SMILES strings.3 Additionally, they were 
able to express more information than SMILES strings. An example is shown for oliceridine in 
Figure 1.2. All InChI strings start with ‘InChI=’, followed by the version number and an ‘S’, which 
corresponds to its standardization. Subsequently, there are six layers of information; the first layer 
is the most important and gives the chemical formula, atomic connections, and hydrogen atoms, 
while the others focus on other chemical aspects such as charge, stereochemistry, and isotopes. 
Also, it should be noted that the InChI format is conspicuously more difficult to read than SMILES. 
As seen from Figure 1.2, InChI strings can be long and unwieldy, so a shorter version was also 
developed as a companion to the original. Known as InChI keys, they are 27-character hashed 
versions of InChI strings that allow for extremely fast chemical database searches due to their 
reduced length. Nevertheless, a previous study has demonstrated that a single duplicate for the first 
14 characters could theoretically occur 0.014% of the time in a database of 100 million 
compounds.4 Given that most chemical databases have well below this number of chemical 
compounds, it can be assumed that a duplication will likely not occur. A drawback of using the 
InChI key is that it cannot be converted back to its respective InChI string, thus these two 
descriptors always need to be paired.  
 
 
2.3 Molecular Fingerprints 
Molecular fingerprints provide an abstraction of the chemical features of compounds into binary 
vectors. All have a fixed length for purposes of comparison and can be used to calculate chemical 
similarity mind-bogglingly fast. Though efficient, they likely have the least specific information 
Figure 1.2 – SMILES and InChI Strings for Oliceridine. MarvinSketch was used for drawing and displaying the chemical 
structures, MarvinSketch 18.10.0, 2018, ChemAxon (http://www.chemaxon.com). 
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packed into its form. Over the years, various developments have aimed to squeeze as much 
information into a small space as possible. 
 
Substructure key-based fingerprints consist of a predefined set of substructures, and the number of 
possible bits is defined by their number. One of the most commonly-used fingerprints of this type 
is Molecular ACCess System (MACCS), first developed by MDL Information Systems (formerly 
Molecular Design Limited) in 1979. Interestingly, they were initially intended for use in database 
searching as opposed to virtual screening,5 which is the common method it is used for today. They 
come in two different flavors: one with 960 substructures, and the other with 166 of the most 
interesting substructures with corresponding SMARTS strings for drug discovery.5 Not 
surprisingly, the latter is far more popular in usage. The principle in which these work is that each 
position in the fingerprint corresponds to a substructure. If the compound has the substructure in 
its chemical structure, then the bit will be set to ‘1’. Else, it would be set to ‘0’. A drawback to 
using these types of fingerprints is that they are usually relatively sparse in content, in that they 
will have mostly zeros, as typical molecules will have very few of the substructures.   
 
Path-based fingerprints are constructed by analyzing every possible fragment in a molecule of a 
given linear path length, then hashing them all to produce the fingerprint. An example is given in 
Figure 1.3 for oliceridine, using a path length of 3. Occasionally, bit collisions occur when the 
same bit is assigned to two different fragments. However, this is not a common occurrence and 
can be reduced by increasing the fingerprint length. The Daylight fingerprint, developed by 
Daylight Chemical Information Systems (hence the namesake), is the most used out of all of these 
and typically consists of 1,028 bits.  
 
Circular fingerprints are very similar to path-based fingerprints in that they are hashed from a 
collection of molecular fragments. However, their method of fragment analysis is not based on 
fragments generated in a linear path, but rather, the chemical environment centered around each 
atom within a certain radius. An example for oliceridine is given in Figure 1.4, where a radius of 
2 was used. Here, fragments are generated by moving a certain radius away from a starting atom 
up until a diameter of 4, resulting in 3 fragments for the specified starting atom. The ECFP4 
6 
 
fingerprint is the industry standard, and not surprisingly, it has been shown to be among the best 
performing fingerprints in a recent benchmark that ranked diverse structures by similarity.6   
 
 
2.4 Chemical Table Files 
Another strategy for storing chemical information in a text file is chemical table file family of file 
formats. Originally developed by MDL Information Systems starting in the late 1970’s,7 they have 
become one of the most widely-used file formats, having been adopted by a vast majority of 
computational chemistry software. Of those in the family, I will focus upon the Structure-Data File 
(SDF) format. An example for monosodium glutamate is shown in Figure 1.5. In brief, the file 
Figure 1.3 – Hypothetical 10-bit Path-Based Fingerprint for Oliceridine. A fingerprint with a path length of 3 was used in 
this example. Only fragments found from a single starting atom (green circle) are shown. The path lengths of the fragments 
(0, 1, 2, 3) are numbered in bold. The asterisks (*) denote where there are bit collisions. MarvinSketch was used for 
drawing and displaying the chemical structures, MarvinSketch 18.10.0, 2018, ChemAxon (http://www.chemaxon.com). 
Figure 1.4 – Hypothetical 10-bit Circular Fingerprint for Oliceridine. A fingerprint with a radius of 2 was used in this 
example. Only fragments found from a single starting atom (innermost green circle) and onwards are shown. The diameters 
of the fragments (0, 2, 4) are numbered in bold. MarvinSketch was used for drawing and displaying the chemical structures, 
MarvinSketch 18.10.0, 2018, ChemAxon (http://www.chemaxon.com). 
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starts with three lines of a header block, which is mandatory but can be left empty if desired. This 
is followed by a counts line, which consists of specifications such as number of atoms, number of 
bonds, and so forth. The atoms block provides information about the coordinates and identity of 
the atom, while the bond block describes the connectivity between atoms. 2D coordinates are 
shown in the example, but 3D coordinates are also commonly used. The properties block denotes 
any existing charges or isotopes, as well as ending the molecular description. Up until this point, 
the file is essentially in Molfile format. Thus, SDF is different in that the subsequent associated 
data allow the inclusion of miscellaneous information not allowed in the main form, such as 
Figure 1.5 – Example SDF Format for Monosodium Glutamate.  
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IUPAC name and database identifiers. The tag for the data type is included inside angle brackets 
(‘<’, ‘>’), and the relevant data is placed on the line immediately following it.  
 
Originating from the now-defunct Tripos, the Mol2 format has achieved a similar level of 
popularity and usage as the SDF format. An example of this format for benzene is given in Figure 
1.6. Various aspects are almost identical to the SDF format, where various blocks are designated 
for counts, atom, and bond information, though with different column formatting. Moreover, each 
block is recognized starting with a record type indicator (i.e. @<TRIPOS>ATOM), followed by 
the corresponding data. Apart from these main record type indicators, there exists many others not 
available in SDF format, such as substructures and rotatable bonds.  
 
 
2.5 FASTA File Format 
As a ubiquitous format for proteins, the FASTA file format is a text file containing a head followed 
by the primary structure. On an interesting note, its namesake stems from a legacy sequence 
alignment software of the same name.8 An example for the mouse mu opioid receptor is given in 
Figure 1.7. The first line always begins with an angle bracket, ‘>’, followed with a personalized 
Figure 1.6 – Example Mol2 File Format for Benzene.  
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description of the protein of interest. In the following lines, the primary structure is shown, starting 
from the N-terminus. Though not required, there are typically 80 characters per line; this is because 
old terminals back in the 1980’s were only able to display this much text per line. 
 
 
3. Chemical and Biological Databases 
As the amount of data available to the scientific community increased over time, there became a 
distinct need to catalogue and organize it so that it could be easily accessible. Truly, gone are the 
days of hours-long expeditions to the library in search of publications that may or may not have 
been helpful to the question at hand. Amazingly, there now exist public databases that index data 
anywhere from the primary structures of proteins to various experimental values of ligands for a 
given receptor. To list and survey them would be out of the scope of this section, so I will briefly 
mention some of the more important databases used for the current dissertation.  
 
UniProt is the de facto standard source of information for proteins.9 This database originated from 
the merging of data from European Bioinformatics Institute (EBI), Swiss Institute of 
Bioinformatics (SIB), and Protein Information Resource (PIR) into an entity known as the UniProt 
consortium. The most commonly-used portion of the database is referred to as UniProt 
Knowledgebase (UniProtKB), which is subdivided into Swiss-Prot and TrEMBL. The former 
collection of data is manually annotated and reviewed by scientists for their respective proteins, 
while the latter refers to those that are computationally annotated from genomic data. Not 
surprisingly, TrEMBL contains a far larger quantity of data than Swiss-Prot. Within Swiss-Prot, a 
multitude of information about a protein of interest is available, such as primary structure, post-
translational modifications, function, subcellular localization, and known protein-protein 
interactions.  
 
Figure 1.7 – Example FASTA File Format for Mouse Mu Opioid Receptor.  
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The Protein Data Bank (PDB) is the single largest repository for protein, DNA, and RNA structures 
solved by structural biologists.10 It began as a united effort in the 1970’s to provide the scientific 
community with protein structures coded into punch cards.1 As the Internet came into fruition, it 
became possible to move the data onto an online platform for a higher throughput distribution. 
Thus, the first web-server for browsing the PDB was developed at Brookhaven National 
Laboratory in 1996.11 With the explosion of solved structures starting in the 1980’s, this resource 
became increasingly invaluable to life science researchers around the world.  
 
Chemical databases vary greatly in their content, providing anywhere from pure chemical data to 
experimental data for ligands and proteins. However, the base content of these databases is always 
chemical in nature. First released in 2009, ChEMBL is arguably the most massive database for 
molecules with drug-like properties and biological activity.12 As of the latest release (ChEMBL 
24.1), the database contain 1,828,820 unique compounds corresponding to 12,091 targets and 
15,207,914 activities from 69,861 publications, all manually annotated. A similar database 
founded over a decade earlier at University of California at San Diego is BindingDB,13 which also 
contain a large number of manually-curated affinity data. However, it has less of a focus on 
membrane receptors than ChEMBL and more strongly emphasizes enzymes targets.14 DrugBank 
is a chemical database whose topic of interest is information on drugs and their corresponding 
targets.15 Another interesting database of note is Psychoactive Drug Screening Program’s (PDSP) 
Ki database,
16 which houses a sizeable number of experimental affinities. A large portion of their 
data is dedicated to G protein-coupled receptors (GPCR). Also, the International Union of Basic 
and Clinical PHARmacology’s (IUPHAR) Guide to Pharmacology is a chemical database that 
deals primarily with popular pharmacological targets, such as GPCR’s and ion channels.17 It is 
manually curated by experts, and only ligands that have been well characterized are included. In 
contrast, ChEMBL, BindingDB, and PDSP Ki are looser in their criteria for inclusion, where the 
binding mode or mechanism are largely unknown for most ligands. Lastly, PubChem is a pure 
chemical database maintained by the National Center for Biotechnology Information (NCBI),18 
containing approximately 93.9 million chemical compounds. Additionally, they have a gargantuan 
collection of bioactivity data from about 1.25 million high-throughput screening campaigns, each 
with several million values.  
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One of the most interesting aspects of chemical and biological databases is their interconnectivity 
to one another. In each chemical database, chemical compounds have a unique ID for identification 
purposes. For example, the ID for morphine in DrugBank is DB00295, while that for the same 
compound in ChEMBL is CHEMBL70. In many of the large databases, cross-references are 
provided so that other databases can be accessed for the same compound. Alternatively, ID 
mapping files are sometimes provided to facilitate the mapping between databases. Another 
important feature of most chemical databases is the utilization of chemical line notation, such as 
SMILES and InChI, for substructure or chemical similarity searching. Alternatively, the user can 
typically draw the molecule into a web applet, which would get translated into chemical line 
notation, as well. Finally, the data from these databases are all downloadable, which form the basis 
of the data used in many areas of chemoinformatics and bioinformatics research.  
 
4. Concepts in Bioinformatics 
The field of bioinformatics is concerned mainly with working on biological problems with 
computers when infeasible with manual human ability. The necessity for computers in biological 
problems first began when the first protein and nucleic acid sequences were acquired. One can 
only imagine the difficulties and tedium of having to compare multiple sequences by eye, thus 
having an algorithm compute the alignments proved to be the best tool for the task. From there, 
the field blossomed beyond sequences into the prediction of macromolecular structure of proteins, 
analysis of the regulation of gene and protein expression, and understanding of networks 
concerning protein interactions. Certainly, bioinformatics has grown into an important discipline 
in its own right and to cover it in its entirety would warrant a textbook. However, basic concepts 
used in this dissertation will be covered in this section as follows. 
 
4.1 Sequence Alignment 
Before the advent of sequence alignment algorithms, pioneering work in the analysis of the 
substitution of amino acids in the primary structure of proteins was performed by Margaret 
Dayhoff in 1978, which led to the development of the Point Accepted Mutation (PAM) matrix.19 
The premise of this was to check for the frequency of amino acid substitutions observed in nature 
among closely-related homologues. Phylogenetic trees were manually constructed for each of 71 
families of proteins with at least 85% sequence identity. For each branch in the phylogenetic trees, 
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the number of mismatched amino acids and their identity were recorded. For all 20 amino acids, 
the propensity for one residue to mutate to another was evaluated, which led to a 20 x 20 frequency 
table. The values from this table were ultimately transformed into a log odds values and became 
what is known as a substitution matrix. Another attempt was made in redefining the substitution 
matrix by Jorja and Steven Henikoff in 1992, which resulted in the BLOcks SUbstitution Matrix  
(BLOSUM) matrix.20 While Dayhoff’s PAM matrix was based on sequences with high global 
similarity, the BLOSUM matrix was derived on blocks that consists of un-gapped regions of 
aligned primary structures. Similar to PAM, the propensities for the substitution of one residue for 
another were calculated and converted into log odds ratio. Because of how they were designed, 
each matrix has their own set of strengths. The PAM matrix is better for tracking the evolutionary 
origin of proteins, while the BLOSUM matrix is great for finding conserved domains.21 
 
A seminal publication from Needleman and Wunsch in 1970 presented an algorithm for the 
alignment of amino acid sequences using dynamic programming. What this algorithm aims to find 
is an optimal alignment based on the global similarity of two given sequences. A matrix m x n is 
constructed, where m and n are the lengths of the first and secondary sequences, respectively. Each 
position in the matrix is scored by either insertion of a gap (up or left) or an alignment (diagonal). 
The former typically consists of a gap opening or gap extension penalty, depending on the current 
direction, while the alignment score will be taken from a scoring matrix, such as PAM or 
BLOSUM. The highest of the three sub-scores will be taken, and the direction will be recorded. 
After all possible paths have been computed, the algorithm backtracks starting from the last aligned 
residues for both sequences. The path with the highest scores is taken and stops when the first 
aligned residues are reached. The Smith-Waterman algorithm is a variation of the Needleman-
Wunsch algorithm in that it performs a local sequence alignment as opposed to global. Here, 
negative scores are set to zero, while the traceback starts instead on the cell with the highest score 
and ends when zero is reached. As a result, this is how local alignment is made possible. 
Additionally, the Gotoh extension to the Needleman-Wunsch algorithm allowed for the favoring 
of long consecutive gaps, as opposed to a collection of short gaps, with the introduction of the 
affine gap penalty.22 Though sequence alignment with dynamic programming is thorough and can 
yield optimal sequence alignments, its application to large databases with millions of sequences 
results in long computation times due to its need to compute every possibility in the alignment. 
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Thus, heuristic methods (i.e. something not optimal but sufficient for reaching the end goal) were 
developed to speed things up by orders of magnitude. 
 
Basic Local Alignment Search Tool (BLAST) is a landmark heuristic sequence alignment 
algorithm developed in 1990 by various scientists at NCBI.23 In brief, the reference sequence is 
broken down into k-letter words. Words matching a sequence in the database are then scored based 
on how well they match, then the high-scoring words are retained. If there is an exact match 
between a high-scoring word and the sequence, then this serves as a seed for an un-gapped 
alignment. If the alignment scores above a threshold value, then it is considered a match. Using 
this method, a large database of sequences can be aligned with a reference sequence in a short 
amount of time. A variant of BLAST called Position-Specific Iterative Basic Local Alignment 
Search Tool (PSI-BLAST) was developed in 1997 again at NCBI, which included some of the 
same scientists from the original version.24 This algorithm made it possible to discover distant 
relationships between proteins. It operated by first running BLAST on a reference sequence against 
a sequence database. Any proteins sequences found that are above a threshold are retained and 
used to construct a Position-Specific Scoring Matrix (PSSM); this is a L x 20 scoring matrix based 
on the amino acid conservation information for each residue of the reference sequence for each of 
the 20 amino acid residues among the aligned sequences. From the second iteration onwards, the 
PSSM is used for scoring, and any new protein sequences found above a threshold are retained for 
the re-generation of the PSSM. This is typically repeated 3 times or until convergence. Overall, 
both BLAST and PSI-BLAST have revolutionized bioinformatics, providing an efficient tool for 
the analysis of a large amount of sequence data. 
 
In contrast with pairwise sequence alignment methods such as BLAST, multiple sequence 
alignment methods operate by comparing a set of homologous protein sequences, such as GPCR’s, 
and can thus reveal conserved motifs or residues. Importantly, it should be noted that an all-
against-all comparison is made, where every sequence is aligned to each other for the optimal 
alignment. Motifs have been found using multiple sequence alignment, such as GCM motif for 
DNA-binding activity.25 Clustal Omega is one of the best algorithms freely available today for this 
purpose, being able to efficiently, accurately align hundreds of thousands of sequences in only a 
few hours.26 
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4.2 Structure Alignment 
There exist numerous metrics for the evaluation of the superposition of two distinct structures. 
Root-Mean-Square Deviation (RMSD) is frequently-used to measure the average distance between 
the atoms of two superposed protein structures, given as follows: 
 
𝑅𝑀𝑆𝐷 = √
1
𝑛
∑((𝑣𝑖,𝑥 − 𝑤𝑖,𝑥)
2
+ (𝑣𝑖,𝑦 − 𝑤𝑖,𝑦)
2
+ (𝑣𝑖,𝑧 − 𝑤𝑖,𝑧)2)
𝑛
𝑖=1
 
 
where there are n points corresponding to proteins v and w in three dimensions, x, y, and z. During 
the structure alignment, this value is minimized to represent the best superposition in three-
dimensional space. For many applications, RMSD is usually sufficient for general structural 
comparison. However, deficiencies in this metric arise when local errors in structure affect the 
overall score. For example, two proteins with a similar fold may visually superpose well, but the 
RMSD may be very high due to equal weight on all pairwise alignments. Furthermore, 
comparisons between large proteins will result in higher RMSD values, which can be misleading. 
As a result, the Template Modeling (TM)-score was developed by Yang Zhang in 2004, originally 
for the assessment of protein structure template quality in threading.27 The equation is shown as 
follows: 
 
𝑇𝑀 − 𝑠𝑐𝑜𝑟𝑒 = 𝑚𝑎𝑥 [
1
𝐿𝑡𝑎𝑟𝑔𝑒𝑡
∑
1
1 + (
𝑑𝑖
𝑑𝑜(𝐿𝑡𝑎𝑟𝑔𝑒𝑡)
)2
𝐿𝑎𝑙𝑖𝑔𝑛𝑒𝑑
𝑖
] 
 
where Ltarget and Laligned are respectively the lengths of the target protein and aligned region, di is 
the distance between the ith pair of residues, and 𝑑𝑜(𝐿𝑡𝑎𝑟𝑔𝑒𝑡) = 1.24√𝐿𝑡𝑎𝑟𝑔𝑒𝑡 − 15
3 − 1.8 is a 
distance scale for normalization. During a structure alignment, this value is maximized; the range 
of the score is between 0 and 1, with 1 being a perfect match. A TM-score above 0.5 denotes that 
the pair of proteins likely belong to the same fold.28 
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Structure has been previously shown to be more conserved than sequence.29 Though it is well-
known that homologous proteins can be found by sequence alignment, this is not always the case 
for proteins with distant homologues with the same fold, due to low sequence identity. Thus, TM-
align was written as a means to generate accurate, fast structural alignments for different proteins.30 
In brief, initial alignments are first made based on features such as secondary structure, where they 
are used to generate the first superposition. Subsequently, the first rotation is made based on these 
initial alignments. This process is iterated until the TM-score is maximized. 
 
 
 
4.3 Structure Prediction 
Structural bioinformatics is a branch of bioinformatics concerned with the analysis and prediction 
of macromolecular structure. Despite the explosion in availability of protein structures (Figure 1.8), 
the majority of proteins within the human proteome (~20,000) have yet to be solved. Thus, 
computational models are typically generated for when the experimental structure does not exist. 
Three families of structure prediction exist for proteins: 1.) ab initio modeling, 2.) comparative or 
homology modeling, and 3.) threading or fold recognition. Ab initio methods seek to build protein 
Figure 1.8 – PDB Structure Statistics for Proteins. Data was acquired from the PDB web server: 
https://www.rcsb.org/stats/growth/protein in August 2018. 
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structure models from scratch. Some groups have approached this problem with physics-based 
approaches, such as molecular dynamics simulations. For instance, one study utilized replica-
exchange molecular dynamics simulations on a set of 9 small proteins from the PDB;31 8 of the 9 
structures folded correctly, though the experiment took about 6 months to run. Other strategies 
include using reduced models with only the peptide backbone and side chain centers of mass in 
folding simulations. Algorithms such as QUARK32 and ROSETTA33 are able to produce 
reasonable models, but unfortunately, the resolution of the structures are usually not high enough 
for in-depth analysis. Additionally, typically only small proteins can be folded, due to the high 
computational costs. Comparative modeling methods, such as MODELLER,34 operate under the 
notion that sequence similarity implies structural similarity.35 Homologous proteins with solved 
structures are as used as input for modeling, and when they are below 30% sequence identity, the 
accuracy of the models takes a hit and may end up with an entirely different fold.36 Therefore, the 
usage of this methodology is limited in many cases, when a good homologue with a solved 
structure is not available. In response to this, fold recognition methods aim to overcome this 
drawback by selecting templates for modeling through fold-level homology. This is made possible 
by the prediction that that there is a limited number of folds found in nature.37 Furthermore, it is 
likely that a correct fold will be selected a majority of the time, as there are already approximately 
1,300 folds currently known. Numerous algorithms have been developed in the same vein, such as 
HHpred,38 Phyre,39 and MUSTER.40  
 
Iterative Threading ASSEmbly Refinement (I-TASSER)41-43 is a composite protein structure 
prediction algorithm that begins with secondary structure prediction, fold recognition, and replica-
exchange Monte Carlo simulations. All that is required as input is the primary structure of the 
protein of interest. Following the first simulation, centroids are selected from the clustering of 
structural decoys, then subjected to a second round of folding simulations. After the decoys are 
clustered again, the lowest-energy structures are selected for refinement through the optimization 
of hydrogen bond networks. I-TASSER has been consistently ranked as the top method in Critical 
Assessment of Structure Prediction (CASP), an international benchmark for structure prediction 
algorithms, and has also generated structure models for hundreds of thousands of proteins 
submitted by researchers worldwide. A variant of this algorithm is GPCR-I-TASSER,44 which was 
specifically designed to predict the structure of GPCR’s. When no suitable template is found, the 
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transmembrane domain undergoes ab initio folding. Experimental restraints from GPCR-RD45 
guide the folding simulations, while a membrane repulsive potential keeps non-TM domains from 
being inserted into the virtual cell membrane.  
 
4.3 Function Prediction 
Another problem in bioinformatics is the assignment of biological function to an uncharacterized 
protein with a known sequence. This can be accomplished in a variety of ways, including inference 
from sequence and structure. One algorithm, COFACTOR46-47, combines sequence, structure, and 
protein-protein interaction into a consensus prediction for Gene Ontology (GO) terms48, which is 
standardized vocabulary for the annotation of proteins. Another algorithm, COnsensus ApproaCH 
(COACH)49, utilizes experimental protein-ligand structure data from BioLiP50 to predict the 
binding site of the query protein. In essence, it is a meta-algorithm that employs other state-of-the-
art binding site prediction software, such as COFACTOR46, FINDSITE,51 and ConCavity.52 
Additionally, TM-STE and S-SITE, respectively employing structure- and sequence-based 
methods for the detection of binding pockets, were developed specifically for COACH. Altogether, 
the top-scoring predictions from each algorithm are fed into a previously-trained support vector 
machine model, producing a final consensus prediction. Continuous Automated Model EvaluatiOn 
(CAMEO), similar to CASP, is a community-wide effort to benchmark the accuracy of protein 
structure prediction servers. It also contains a section dedicated to ligand binding site predictions 
in proteins, in which COACH consistently performs better than its competitors.  
 
5. Concepts in Chemoinformatics 
Similar to bioinformatics, chemoinformatics is concerned with the analysis and processing of large 
amounts of data, though affiliated with chemistry. In this section, various concepts in 
chemoinformatics will be introduced to provide a glimpse into the processing of chemical data 
with computers. 
 
5.1 Chemical Similarity 
Molecular fingerprints, as described previously in the chapter, are most often used in the 
calculation of chemical similarity. As a brief refresher, they are composed of a fixed-length string 
of bits; the presence of ‘1’ in a position denotes the presence of a chemical fragment, while ‘0’ 
18 
 
denotes its absence. The simplicity of this form allows for the possibility of dreadfully fast 
calculations. A multitude of similarity metrics are available, but the Tanimoto coefficient has 
proven to be among the best and therefore has been most in use.53 The equation is shown as follows: 
 
𝑇𝑎𝑛𝑖𝑚𝑜𝑡𝑜 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =  
𝑐
𝑎 + 𝑏 − 𝑐
 
 
where a is the number of bits in the first molecule, b is the number of bits in the second molecule, 
and c is the number of shared bits between the two molecules. A visual representation for 
calculation of the Tanimoto coefficient is given in Figure 1.9 for hypothetical 10-bit fingerprints. 
Only the same type of molecular fingerprint can be compared among molecules and mixing 
different types will lead to erroneous results.  
 
 
5.2 Cluster Analysis 
In many chemoinformatic applications, it is often necessary to group the data by some quantitative 
means for classification purposes. This is known as cluster analysis or clustering. Frequently-
occurring chemotypes can be revealed this way and thus provide insight into a collection of 
chemical compounds. In many of the applications throughout this work, various clustering 
algorithms were employed to isolate groups of chemically-similar compounds. 
 
The Taylor-Butina algorithm54-55 is a non-hierarchical, unsupervised clustering method. For every 
chemical compound in a set, the chemical similarity is calculated using the corresponding 
Figure 1.9 – Sample Tanimoto Coefficient Calculation. Hypothetical 10-bit fingerprints are given for molecules A and B. 
2 bits are shared between the two molecules, while molecules A and B respectively have 4 and 6 bits in their form. The 
Tanimoto coefficient (TC) is calculated to be 0.25, which means that there is 25% similarity between the two molecules. 
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molecular fingerprints. Neighbors are acquired based on a similarity threshold, which is user 
defined, and become members of the cluster if they meet the threshold. Subsequently, the 
compounds (centroids) are sorted in descending order based on the number of members they have. 
Starting from the centroid with the largest number of neighbors, an exclusion sphere is set that 
flags the members of the cluster, disallowing them from becoming a centroid or a member of 
another cluster. Chemical compounds with no neighbors are referred to as singletons, as they bear 
no chemical similarity with any other in the set. Moreover, every cluster is guaranteed to have a 
neighbor at least the similarity cutoff of the centroid.  
 
LibMCS from Chemaxon is a hierarchical clustering algorithm rooted in chemical substructure. 
Though the algorithm is proprietary, the method is straightforward, and a description is provided 
by the company website.56 First, chemical compounds are decomposed to chemical graphs, and 
clusters are formed where the compounds share the same substructure. This process is then 
repeated for further levels of clustering for each cluster until a single common substructure is 
acquired or until a size threshold for a substructure is reached. This ultimately results in a 
dendrogram, such as that shown in Figure 1.10. Indeed, this is a powerful method that can be used 
Figure 1.10 – Clustering with LibMCS. Three levels of clustering are shown, with the starting chemical compounds being 
at the first level (bottom). MarvinSketch was used for drawing and displaying the chemical structures, MarvinSketch 
18.10.0, 2018, ChemAxon (http://www.chemaxon.com). 
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to group sets of chemical compounds with the same substructure and is useful because they likely 
have similar bioactivities. Furthermore, there is a greater level of user specification as to which 
clusters at which level to analyze, as opposed to a single clustering output generated from methods 
like the Taylor-Butina algorithm. Overall, there is no best clustering method, and it all boils down 
to which one is suitable for the question at hand.  
 
5.3 Molecular Docking 
Though not technically a chemoinformatic technique, the abundant results from docking-based 
virtual screens are regularly subjected to processing with chemoinformatics. Molecular docking is 
a method used in computational chemistry to predict how a ligand binds with a receptor through 
scoring functions. Prior knowledge of the binding site is typically required in order to specify the 
area to be examined. Protocols for most docking programs start with adding hydrogens and partial 
charges to both the receptor and the compounds. This is then followed by the docking algorithm 
doing a conformational search of the most favorable ligand pose, which is evaluated with a scoring 
function at each step. Subsequently, the top poses are generated for the user, who can then visually 
check with a molecular viewer. Additionally, the final scores for each model are also given. 
 
There have been dozens of docking software developed over the years, and each has approached 
docking in a different way. Some of the major differences between these are: 1.) the search 
algorithm, 2.) scoring function, and 3.) flexibility of ligand or receptor. Among the top methods 
employed for conformational searches are the Lamarckian genetic algorithm (AutoDock57), 
genetic algorithm (GOLD58), local search global optimizer (AutoDock Vina59), ant colony 
optimization, (PLANTS60), anchor-and-grow (DOCK 661), and exhaustive search (Glide62-63). 
Though these strategies differ greatly in their search algorithms, their basic premise remains the 
same; that is, they aim to achieve the most favorable ligand pose. To do so, a scoring function must 
be calculated at each step of conformational sampling to evaluate the pose. Many of the ones used 
currently are physics-based force fields that approximate the binding energy of the ligand pose in 
the binding site. For example, the scoring function from DOCK 6 simply uses van der Waals and 
electrostatics terms for computational efficiency.64 Various others take other physical terms into 
account, such as hydrogen bonding, desolvation, and hydrophobic contributions.58 Additionally, 
there exist empirical scoring functions, which estimate the binding energy using a set of weighted 
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energy terms, and knowledge-based scoring functions, which utilize energy potentials derived 
from experimentally-solved structures.65-66 Finally, there is the option of how to treat the receptor 
and ligand during docking. Most software packages make the receptor rigid because of the 
computational rigor involved in sampling the receptor conformation. However, some given an 
option to make certain side chains of the receptor flexible, such as AutoDock Vina59 and GOLD.58 
Schrödinger has an induced-fit docking protocol that allows for both ligand flexibility and 
conformational changes in the binding site, though its application to virtual screening of a large 
number of compounds is limited due to its computational intensity. Most of the earliest docking 
methods, such as the original DOCK,67 treated the ligand as a rigid body in order to find molecules 
with shape complementarity to the binding site. Nevertheless, this methodology is limited by the 
conformation of the molecule being docked, whereas vastly different conformations could be 
observed in reality. Therefore, multiple conformers would have to be generated for docking, 
making shape matching methods, such as ROCS from Open Eye Software, a far more attractive 
option. Modern docking algorithms all treat the ligand as flexible, allowing for it to find its most 
optimal pose in the binding pocket of a receptor.  
 
5.4 Virtual Library and Benchmark Design 
It is important that the contents of a virtual library meet the criteria for what a virtual screen is 
aiming. To screen a library of completely random compounds would not be sense in a drug 
discovery setting, as a clear majority would likely not fit the mold of what a typical drug would be 
like. Thus, a virtual library must be fashioned around a certain set of properties corresponding to 
a research question. As a prime example for this concept, ZINC database68 is a database of 
commercially-available compounds available for virtual screening. Multiple subsets of data have 
been pre-compiled, where the chemical compounds have been selected using various property 
filters. For example, the drug-like subset is filtered by Lipinski’s rule of five, which evaluates a 
compound based on a set of chemical and physical properties;69 in order to be druglike, it must 
have: 1.) no more than 5 hydrogen bond donors, 2.) no more than 10 hydrogen bond acceptors, 3.) 
molecular weight of between 150 and 500 Daltons, and 4.) an octanol-water partition coefficient 
of not greater than 5. In another subset, the compounds are filtered based on rules defined by 
Teague et al for lead-like compounds,70 where they pass if they are: 1.) between 250 and 350 
Daltons in molecular weight, 2.) an octanol-water partition coefficient of no greater than 3.5, and 
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3.) no more than 7 rotatable bonds. In another study involving the serotonin receptor, ZINC 
database was filtered for compounds containing one or more aliphatic nitrogens, a characteristic 
feature found in most serotonin receptor ligands.71 The design of these types of focused virtual 
libraries is required for the success of a virtual screen in an experimental setting. 
 
 
In chemoinformatics, benchmarks datasets are used to provide a gold standard for the comparison 
of the performance of algorithms. The premise involves testing the ability an algorithm in 
distinguishing known active compounds from among a sea of decoy molecules. The Directory of 
Useful Decoys (DUD)72 and its successor, DUD-Enhanced (DUD-E),73 will be used as examples 
for successful design with docking benchmarks. For every receptor, the original study that 
developed DUD generated 33 decoys per active compound that were chemically similar but 
topologically different. However, a few drawbacks were found for this method. First, several 
chemotypes were overrepresented in many data sets.74 Second, some of the sets had a very low 
number of active ligands, indicating the need for more.73 Last, it was observed that the net formal 
charge of was imbalanced between the actives and decoys.75 Thus, DUD-E was designed to 
address all of these issues from the first variant. Actives were now drawn through ChEMBL 
database in bulk and filtered by bioactivity, solving the deficiency in active compounds for some 
sets. Furthermore, more attention was drawn to balancing out charged compounds between actives 
and decoys. Most importantly, overrepresentations of certain chemotypes was eiminated by the 
clustering of Bemis-Murcko frameworks.76 An example of a decomposition into a Bemis-Murcko 
Figure 1.11 – Decomposition of Oliceridine into a Bemis-Murcko Framework. First, all non-carbon atoms are converted 
to carbon, and aromaticity and stereochemistry are removed. Then, all side chains not linking to another ring are removed. 
MarvinSketch was used for drawing and displaying the chemical structures, MarvinSketch 18.10.0, 2018, ChemAxon 
(http://www.chemaxon.com). 
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framework is given in Figure 1.11. Actives having the same framework were clustered together, 
and based on a set of rules, a certain number were chosen from each cluster so that there were 
between 100 and 600 for each set.  
 
5.5 Virtual Screening 
High throughput screening is an essential methodology in the pharmaceutical industry for the 
screening of chemical libraries for hits against a drug target. Due to its being costly, time-intensive, 
and laborious, virtual screening (or in silico screening) has emerged as a complementary strategy 
to reduce the chemical search space and to prioritize hits for experimental validation. Virtual 
screens can typically be categorized as ligand based and structure based, depending on what 
algorithm is used; the former utilizes pure chemical information in its search process, whereas the 
latter uses structural information to determine how well a compound would bind. As with any 
method, there are advantages and disadvantages to each. Ligand-based methods, such as chemical 
similarity, are computationally inexpensive and can screen millions of compounds within a short 
time but have the drawback of being biased towards the known ligands used to build the model. 
Conversely, structure-based methods, such as molecular docking, inherently have no bias, but they 
are extremely computationally expensive. A trend in recent years has culminated in the 
combination of these methods to address their respective shortcomings.77  
 
Validation of virtual screening methods can be categorized as retrospective or prospective. In 
retrospective methods, the screening is usually performed where a certain amount of known active 
compounds and inactive compounds or decoys are all scored and ranked. The goal here is to try 
and get as many active compounds into the top-ranking portion of the list as possible. A typical 
metric for evaluation is the enrichment factor of the top 1%, given as follows: 
 
 
where 𝑁𝑎𝑐𝑡 and 𝑁𝑡𝑜𝑡 are the total numbers of the active and all compounds, respectively. 𝑁𝑎𝑐𝑡
1% 
and 𝑁𝑠𝑒𝑙𝑒𝑐𝑡
1%  are, respectively, the numbers of active ligands and the number of all candidates in 
𝐸𝐹1% =
𝑁𝑎𝑐𝑡
1%
𝑁𝑠𝑒𝑙𝑒𝑐𝑡
1% 
𝑁𝑎𝑐𝑡
𝑁𝑡𝑜𝑡
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the top 1% of the ranked database. An illustration of different results achievable in a 
retrospective virtual screen is given in Figure 1.12.  
 
 
A drawback of retrospective virtual screens is that no real results will have been produced that 
officially translate to biology. They are usually run to benchmark algorithms or to validate the 
virtual screening model before choosing compounds for experimental validation, and hence, they 
are useful in that regard. However, a model will always just be a model, and the only practical way 
to verify whether a virtual screen resulted in a prediction of any merit would be to test the 
compounds in the lab. They are usually chosen based on various criteria, such as manual inspection 
of the ligand-receptor complex for key interactions or chemical diversity. The usual metric for 
success is the hit rate, which is the percent of selected compounds that were considered active. 
This is not the greatest measure used, as the selection can be very subjective. Moreover, there is a 
risk of underreporting inactive compounds to boost the hit rate. Nevertheless, it remains an 
unwritten standard in the field to list hit rates as a measure of how successful the virtual screen 
was. 
 
 
Figure 1.12 – Illustration of Enrichment Factors from Retrospective Virtual Screens. Assume that there 10 total 
compounds at the top 1% of the ranked database (dark gray), 1,000 compounds overall (dark gray + light gray), and 100 
total active compounds. Each active compound is represented as a yellow bar in the top 1%. (I.) In this example, no actives 
were retrieved, thus the algorithm would be considered performing worse than random. (II.) Only 1 out of the 100 actives 
were acquired, so this would be considered random. (III.) In this scenario, 10 actives were found in the top 1%, performing 
greater than random. 
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6. G Protein-Coupled Receptors 
G protein-coupled receptors (GPCR) have been an important target in drug discovery, as they 
represent the target for almost a third of all drugs on the market. Marked by their distinctive seven-
pass transmembrane domain, the GPCR superfamily astoundingly accounts for almost 5% of the 
human proteome. Consequently, the function of each member varies widely from pain modulation 
to vision. In this section, I will provide a brief overview of the biology of GPCR’s, as well as 
applications of computer-aided drug design. 
 
6.1 Family Organization 
Originally, GPCR’s were observed to contain members sharing very little sequence similarity with 
others, hinting at the existence of distinct families (a.k.a. classes) within the superfamily.78 Further 
on down, phylogenetic analysis of GPCR primary structures with PSI-BLAST proposed a division 
into the following families:79 
• Class A – Rhodopsin-like 
• Class B – Secretin-receptor Family 
• Class C – Metabotropic Glutamate / Pheromone 
• Class D – Fungal Mating Pheromone Receptors 
• Class E – Cyclic AMP Receptors 
• Class F – Frizzled / Smoothened 
Alternative classifications include the GRAFS system (Glutamate, Rhodopsin, Adhesion, Frizzled, 
Secretin), which separated out the adhesion receptors from Class B.80 Of these, the Class A 
GPCR’s by far outnumber the other families. Additionally, it was later stratified into 19 subgroups 
following phylogenetic analysis.81 One of these subgroups, the olfactory receptors, comprise a 
whopping 390 members out of 719 Class A receptors. Class D and E GPCR’s are usually excluded 
from vertebrate-based studies, as they are of fungal and slime mold origin, respectively. Type 2 
taste receptors, which have been linked to detecting bitterness, have been distantly linked with 
Class A GPCR’s; they are also sometimes separated out into their own group.82 Clearly, the 
classification of GPCR’s has been an arduous task that has taken decades to come to fruition, and 
thankfully there now stands a relatively clear-cut organizational system. 
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With such a large number of GPCR’s, there will undoubtedly be members that have had not been 
study as rigorously. These are referred to as orphan receptors, having no known endogenous ligand 
or function. According to IUPHAR,17 there are currently 87 Class A GPCR’s, 8 Class C GPCR’s, 
and 26 adhesion GPCR’s that are still not well understood. The process of de-orphanisation is 
aimed at elucidating the pharmacology of these receptors in order to shed some new light on 
potentially medically-relevant conditions. Since the 1980’s, there have been dozens of success 
stories in the de-orphanisation of GPCR’s,83 and it is only a matter of time before the function and 
endogenous ligands of all members are revealed. 
 
6.2 Structure and Physiological Roles 
All members of the GPCR superfamily share the characteristic seven-transmembrane domain that 
winds through the plasma membrane in a serpentine fashion. Additionally, they contain an N-
terminal domain, C-terminal tail, 3 extracellular loops, and 3 intracellular loops. Not surprisingly, 
the most conserved regions lie in the transmembrane domains, where the original classification 
has been shown to be approximately replicated using only the transmembrane domains.84 
Moreover, this is the classical site where ligand binding occurs for many Class A receptors and 
was also replicated for this family using only the binding site residues in a previous study.85 
Interestingly, the barrel-like fold of the TM domain is highly conserved and observed in all solved 
structures (Figure 1.13B). The N-terminal domain is oriented to face the extracellular matrix and 
participates in ligand binding, while the C-terminal faces the cytosol and is involved with the 
association with downstream effector proteins (Figure 1.13A). 
 
Since 2000, the number of solved GPCR structures in all families has skyrocketed, revealing a 
wealth of information about how they function through their structure. Both active- and inactive-
state structures have been produced, with the former kind bound with either heterotrimeric G 
protein complexes or β-arrestin. Many of the structures have ligands bound, though a smaller set 
contain allosteric modulators. Truly, the history of GPCR structural biology is a fascinating topic, 
and thus, a comprehensive review of this will be given in Chapter 2. Lastly, details of receptor 
activation  with respect to structure will not be discussed, as it is beyond the scope of the 
dissertation, though a good review of this topic exists by Katrich et al.86 
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GPCR’s are involved in a wide range of physiological roles in higher vertebrates and likely arose 
through multiple gene duplication events.87 The duplicates would have had little evolutionary 
pressure, allowing them the freedom to mutate and develop new functions. This has resulted in 
roles as far flung as olfaction to light perception. Besides being involved in various senses, they 
have also played roles in fight-or-flight response and pain modulation. However, many GPCR’s 
have important signaling pathways that could lead to diseases when dysregulated by mutations.88 
For example, activating mutations in the thyroid-stimulating hormone receptor have been shown 
to cause thyroid carcinoma,89 while inactivating mutations in the same receptor were associated 
with hypothyroidism.90 Other diseases, such as addiction, have been shown to be caused by the 
kind of ligand be used. In the case of the mu opioid receptor, an unwanted signaling pathway is 
activated enough to the point where the development of addiction can develop.91 No matter the 
cause of the disease, the development of therapeutic compounds targeting GPCR’s has remained 
an important part of drug development in order to combat suffering. 
 
 
Figure 1.13 – Structure of Mouse Mu Opioid Receptor. The structure was taken and modified from the structure with 
PDB ID: 5C1M.  (A.) A side view is shown to emphasize the cellular localization of the GPCR. (B.) A top-down view 
from the perspective of the extracellular matrix is shown to emphasize the conserved, barrel-like topology. 
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6.3 Application of Computer-Aided Drug Design  
To date, there exist a plethora of prospective virtual screening campaigns applied to GPCR’s. 
Some interesting studies have included the discovery of: 1.) a biased agonist for the mu opioid 
receptor,92 2.) selective agonists for the serotonin 1B receptor over the serotonin 2B receptor,71 
and 3.) antagonists for the C-X-C chemokine receptor 4.93 Though there have been numerous 
computational studies claiming to have found the next greatest potential drug, the question bugging 
countless experimentalist scientists remains: Does computer-aided drug design actually produce 
compounds that make it to clinical trials? The answer would be a resounding ‘yes’.  
 
In 2006, a group from Predix Pharmaceuticals (now known as Epix Pharmaceuticals) ran a 
docking-based virtual screen on a homology model of serotonin 1A receptor that resulted in a 
potent, selective agonist.94 The reporting came as the drug candidate, Naluzotan, was in a phase 
III clinical trial, though ultimately, it failed to perform better than the placebo and was 
discontinued.95 In another study from Heptares Therapeutics, a novel adenosine A2A receptor 
antagonist was discovered through a docking-based virtual screen on homology models, called 
AZD4635.96 It is currently in phase I clinical trials. These are but a fraction of success stories 
stemming from computer-aided drug design, but this is proof enough that the field has undoubtedly 
been advancing to produce viable results.  
 
7. Goal of Dissertation 
In the following two chapters, I introduce two GPCR-related databases in which I developed. The 
first to be introduced is GPCR-EXP, a semi-manually curated database for experimentally-solved 
and predicted GPCR structures, which was created in response to other resources being slow to 
update and not user friendly. Next, GLASS database was constructed, which processes and unifies 
GPCR experimental data from various other pharmacological and biological databases. To date, it 
is the largest database of its kind and was made to fill in the gaps of other similar databases that 
have ceased updates.  
 
The latter two work-related chapters delve deeper into algorithm development using 
bioinformatics and chemoinformatics, as well as its application. In the 4th chapter, I discuss the 
development of MAGELLAN, which is a ligand-based virtual screening algorithm that 
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incorporates sequence and structure information, and data from GLASS database was heavily 
involved in its usage. Its purpose was primarily to aid in the de-orphanisation of GPCR’s, but it 
could also be used as for general ligand-based virtual screening. Finally, the 5th chapter builds on 
the work from MAGELLAN by coupling it with a docking-based virtual screen. The goal of this 
work was to discover novel bifunctional compounds that act as agonists towards the mu opioid 
receptor and as an antagonist towards the delta opioid receptor, which would potentially lead to a 
safer opioid with reduced tolerance and withdrawal.  
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CHAPTER 2.  
GPCR-EXP: A Semi-Manually Curated Database for Experimentally-Solved 
and Predicted GPCR Structures 
 
1. Introduction 
G protein-coupled receptors (GPCR) constitute one of the largest family of transmembrane 
proteins and have been implicated in a multitude of human diseases, such as cancer and diabetes.1 
With the rapid rise and availability of GPCR structures within the past decade, structure-based 
drug design has become a prominent area in drug development utilizing structure to facilitate the 
optimization of known compounds or to provide a means for virtual screening.  
 
The centralized resource that houses all three-dimensional structural data for biological 
macromolecules is the Protein Data Bank (PDB).2 As such, all GPCR structures are submitted and 
stored in this database, so that the scientific community can effortlessly access this data. However, 
there is no easy way to survey the breadth of GPCR structures within the confines of PDB, and 
thus, researchers have to rely upon manually sifting through the scientific literature to identify 
which structures have been solved. This process can be cumbersome and ineffective, and hence a 
database consolidating all aspects of GPCR structural data would be extremely useful in this 
regard. 
 
To our knowledge, there is only one resource, GPCRdb,3 which focuses on experimental GPCR 
structures. Some of the difficulties in establishing such databases are: 1) precise curation of the 
data, 2) timely updates, and 3) usability of the web interface. As GPCR structures are increasingly 
being released at a higher rate, the time in between database updates can greatly affect the 
availability of new data to the scientific community. Furthermore, purely manual methods of data 
acquisition can lead to inaccuracies and take a long time to curate, while an inefficient database 
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interface with endless options can lead to utter frustration in perusing the information in need. As 
a result, the need for a GPCR structure database addressing such needs is of utmost importance.  
 
Despite the recent renaissance in GPCR structural biology, 1,029 out of 1.076 human GPCR genes 
do not yet have an experimental structure. Therefore, apart from experimental GPCR structures, 
the prediction of GPCR structures holds equal importance. In particular, as many efforts in drug 
discovery utilize structure for drug design, computational methods have been developed to predict 
the protein structure for those targets without a solved structure. Many web servers, such as 
GPCRM,4 GoMoDo,5 and GPCR-ModSim,6 and databases, including GPCR-SSFE7 and GPCRdb3 
rely upon homology modeling with MODELLER8 for generating their structure models. While 
this method works well for targets that have close relatives with known structures, it can be less 
effective when applied to targets with no good homologous structure templates. As a majority of 
human GPCR proteins share less than 30% sequence identity to any experimentally determined 
GPCR structures, a robust structure prediction program capable of modeling distantly or non-
homologous GPCR structures is required. GPCR-I-TASSER is our in-house method that utilizes 
the LOMETS9 meta-threading approach to find templates, from which structure fragments and 
distance restraints are extracted to guide structure assembly simulation. Our method performed 
well in the GPCRDock2010 competition, in which our models were among the most accurate for 
the transmembrane (TM) domains for both the C-X-C chemokine 4 and dopamine D3 receptors; 
this was significant because we achieved the most accurate structure for the former target, which 
was considered very difficult.10 This indicates the ability of GPCR-I-TASSER to produce accurate 
structure models for use in various avenues of drug discovery. 
 
In the present study, we have developed GPCR-EXP, a semi-manually curated database for 
experimentally-solved and predicted GPCR structures. Experimental data is scraped and processed 
from the PDB, producing a comprehensive, accurate collection of protein and ligand data. An 
important feature of the update pipeline for keeping the GPCR data current is the manual curation 
of ligand data, which is crosschecked with PubMed.  Additionally, structure models are generated 
for over 1,000 GPCRs from the human genome, followed by binding site prediction. All data are 
freely downloadable and browsable in a convenient database interface. Weekly updates to GPCR-
EXP’s experimentally-validated GPCR structures will ensure that the GPCR community gets the 
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latest structures on a consistent basis. Lastly, we present a brief analysis of trends in GPCR 
structural biology using the experimental data in GPCR-EXP. 
 
 
 
 
2. Methods 
GPCR-EXP contains data for both experimentally-solved and predicted structures of GPCRs. Data 
for the former are primarily extracted from PDB, while high-resolution structure models and 
binding site predictions are generated for the latter with GPCR-I-TASSER11 and COACH12-13, 
respectively. The pipeline for the acquisition and processing of data for GPCR-EXP is illustrated 
in Figure 2.1.  
 
2.1 Processing Data for Experimental Structures 
The entire data acquisition and processing pipeline was written in Perl, while additional custom 
Python scripts were used for 2D chemical image generation. 
 
Figure 2.1 - GPCR-EXP Pipeline for Data Processing.  
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2.1.1 General Experiment Data 
UniProt IDs are programmatically acquired from ‘7tmrlist.txt’ in UniProt 
(https://www.uniprot.org/docs/7tmrlist.txt), which are then queried against the RESTful API from 
PDB.2, 14 Subsequently, a list of PDB IDs mapped from the UniProt IDs are returned and used to 
scrape data and download PDB structures. 
 
Using the list of PDB IDs, comma-separated value (CSV) report files are scraped from the 
RESTful API from PDB using their ‘Custom Report Web Services’, corresponding to ‘Structure 
Summary Report’, ‘Sequence Report’, ‘Ligand Report’, and ‘Citation Report’. All relevant data, 
such as chain IDs and ligands, from these files are used in the following data processing steps, in 
addition to forming the basis for the compilation of a summary tab-separated values (TSV) file of 
all processed data in one of the final steps. 
 
2.1.2 PDB Structures 
The original PDB structures are downloaded from PDB using their PDB ID. GPCR structures with 
full TM domains are filtered for using the following criteria: 1) they are greater than 150 residues, 
and 2) the full TM domain has at least 80% sequence identity with the corresponding reference 
TM domain from UniProt. With respect to the latter condition, the reference TM domain sequences 
are combined and treated as a single sequence, which is then aligned with the GPCR sequence 
parsed from the PDB file. GPCR structures that have been solved with only the extracellular 
domain or portions of the transmembrane domain are filtered out and included as a separate 
download; for the purposes of this study, these will be referred to as ‘GPCR fragments’.  
 
All GPCR structures with full length TM domains are then processed to isolate a single chain 
representing only the GPCR, removing any fusion (e.g. lysozyme) or associated (e.g. G protein) 
proteins. If the PDB structure has multiple GPCR chains, the chain ID of the GPCR with the 
alphabetically-lowest letter is designated and used for the rest of the pipeline. For purposes of 
viewability, the isolated GPCR structures are structurally aligned with a reference structure using 
TM-align in order to position the GPCR with a side view of the TM domain where the N-terminal 
domain faces up. Moreover, PNG files of the aligned GPCRs are generated using MolScript 15 for 
use as thumbnail images on the web page. 
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Data about fusion and associated proteins are extracted from the ‘Sequence Report’ CSV files on 
the basis of being a non-GPCR protein within the PDB structure. Numerous associated proteins 
are observed to be peptide ligands and typically appeared as a distinct chain in the PDB structure. 
An associated protein is classified as a peptide ligand if there are fewer than 50 residues. 
Interestingly, the largest peptide that we observe is Exendin-P5 (PDB: 6B3J), which contains 40 
residues. All peptides are kept as ligands alongside small molecules, which will be discussed in 
the following section.  
 
 
2.1.3 Ligand Data 
Small molecules are parsed from the ‘Ligand Report’ CSV files. As commonly seen, there is an 
abundance of non-ligand molecules alongside the actual ligand or ligands. Consequently, this 
makes programmatic acquisition of the ligand difficult. To address this problem, we designate 
ligands through manual inspection of the corresponding publication through PubMed. Figure 2.2A 
shows an example case with the platelet-activating receptor (PDB: 5ZKQ). Here, the ligand was 
determined to be the inverse agonist ABT-491 (Figure 2B). Molecules ignored included a 
Figure 2.2 - Ligands for Platelet-Activating Receptor (PDB: 5ZKQ). (A) The structure includes four ligands (ABT-491, 
(2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate, zinc, and sulfate). The former two are shown in black. (B) ABT-491 is 
the ligand, which acts as an inverse-agonist, while (C) (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate is a lipid that assists 
in membrane protein crystallography. MarvinSketch was used for drawing and displaying the chemical structures, 
MarvinSketch 18.10.0, 2018, ChemAxon (http://www.chemaxon.com). 
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detergent used in membrane protein crystallization, (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-
enoate (Figure 2.2C), as well as the ions, zinc and sulfate.  
 
We initially compiled a list of non-ligand molecules following a comprehensive survey of PDB 
structures of GPCRs and incorporated them into a filter. This allowed us to streamline the process 
of verifying ligands while updating the database. If a new molecule appears in an update that the 
database has yet encountered, then it is manually checked and designated as a ligand or added to 
the filter if it is a non-ligand. Over the course of developing the update pipeline, we observed that 
the current filter is sufficient for most of the new GPCR structures coming out recently, indicating 
reoccurrence of common, non-ligand molecules. 
 
PNG images of 2D chemical structures are generated for each ligand through RDKit using their 
respective InChI strings.16 Additionally, both small-molecule and peptide ligands were extracted 
from the original PDB structures as PDB files. Also, it should be noted that allosteric modulators 
were included alongside ligands that bound in the orthosteric site. 
 
2.1.4 GPCR Structure Superposition 
Many GPCRs have multiple PDB structures bound with different ligands or in different activation 
states. For example, the 5-hydroxytryptamine receptor 1B has four PDB structures (PDB: 6G79, 
5V54, 4IAQ, 4IAR) as of the time of preparation of the manuscript. For each GPCR, one structure 
is chosen as the reference, while the others are aligned to it using TM-align.17 All small molecule 
and peptide ligands are included in this step, as well.  
 
2.2 Generating Predicted Structures and Binding Sites 
UniProt IDs for 825 human GPCRs were programmatically acquired from ‘7tmrlist.txt’ in UniProt, 
while 251 additional entries were obtained from TrEMBL. In total, we modelled 1,076 human 
GPCRs in this study, with 703, 49, 22, 11, 44, and 247 from class A, B, C, F, other, and TrEMBL, 
respectively.  
 
The full-length sequence of the human GPCRs were modelled using GPCR-I-TASSER, which 
operates by reassembling structural fragments from threading through replica-exchange Monte 
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Carlo simulations.11 There were a number of GPCRs that had very long sequences. In fact, there 
were 22 GPCRs that had over 1,000 residues, which consisted of a mixture of Class B and C 
GPCRs with gigantic extracellular domains. Though GPCR-I-TASER can model proteins over 
1,000 residues, the models with more than 650 residues are poorly modeled with incompact 
transmembrane helix packing, due to poor template coverage and insufficient conformation 
sampling for long proteins. Thus, for those GPCRs with over 650 residues, we truncated the N- 
and C-termini so that there would be at most 30 residues extending from either side of the TM 
domain. The top 5 models were selected for use in the database. 
 
COACH12-13 is an algorithm developed to detect ligand binding residues through composite 
sequence-profile and structure comparisons and was thus used to predict the binding site for the 
top model from GPCR-I-TASSER. 
 
2.3 Web Server Construction 
The web server was constructed on top of a MySQL database. The server side was coded with a 
combination of Python CGI scripting and PHP, while the client side was controlled with 
JavaScript. NGL Viewer was used to display all protein structures,18 and Plotly facilitated the 
visual display of graphs for database statistics. Lastly, the jQuery plugin, tablesorter 
(https://plugins.jquery.com/tablesorter/), was used to generate the data tables. 
 
3. Results 
3.1 Brief Analysis of GPCR-EXP 
As of the time of writing, GPCR-EXP contains 271 unique, experimental GPCR structures. A total 
of eight species is represented in this set, ranging from common species such as Homo sapiens and 
Mus musculus to more uncommon ones, such as human cytomegalovirus (strain AD169). 
Additionally, there are 52 unique types of GPCRs that have been solved independent of species, 
such as the mu opioid receptor. We also modelled the structures of 1,076 human GPCRs, as well 
as predicted their binding sites. 
 
Analysis of the experimental data of the GPCR structures reveals fascinating trends in structural 
biology. As has been frequently observed in recent years, the rate of release of GPCR structures 
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has been steadily increasing (Figure 2.3). In particular, the number of structures solved in the 
current year (as of July 27, 2018) is 42, as compared to 46 in 2017. Being only halfway through 
the year, it is very likely that the amount of releases in this year will dwarf the previous. One 
interesting observation is that no GPCR structures were solved in 2009. Up until then, the only 
available GPCRs were rhodopsin, β1 and β2 adrenergic receptors, and A2A adenosine receptor; 
the chemokine CXCR4 receptor was the first new GPCR to be released in 2010 after the drought 
of 2009. With the current overrepresentation of rhodopsin (50 structures), β1 and β2 adrenergic 
receptors (39 structures), and A2A adenosine receptor (45 structures) among all the GPCR 
structures, it is likely that they are easier to crystallize or have a better-established protocol than 
the others.  
 
 
 
Starting from 2000, all of the GPCRs initially solved were Class A GPCRs. This is not a surprising, 
as they constitute the majority of members in the superfamily. However, it took until 2013 for the 
first Class B and F GPCRs to finally be solved,19-21 while it took until the following year to finally 
get a solved structure for Class C GPCRs (Figure 2.4A).22-23 For each year up until 2017, non-
Class A GPCRs have constituted at most only ~10% of all structures per year. Regardless, their 
proportion has grown in recent years, and their prevalence is expected to increase due to their 
medical relevance. Another interesting facet of GPCR structural biology was the inclusion of 
Figure 2.3 - Cumulative Number of Experimentally-Solved GPCR Structures Over Time. The first GPCR structure ever 
solved was in 2000. Since then, structures have been released at higher rates in recent years, likely due to advances in the 
field. Note that no structures were solved in 2009. 
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fusion proteins to facilitate the formation of crystal contacts in crystallography. Starting in 2007, 
Cherezov et al was the first study to engineer a chimeric GPCR construct, where the third 
intracellular loop was replaced with lysozyme.24 In 2012, researchers started using soluble 
apocytochome b562 (i.e. bRIL), and this has steadily grown in popularity, having largely replaced 
lysozyme in recent years (Figure 2.4B). Meanwhile, other fusion proteins (rubredoxin, flavodoxin, 
and GlgA glycogen synthase) have also been used to lesser extents.  
 
 
Another aspect we examined was structural resolution and number of point mutations used with 
GPCR constructs. The resolution of the structure of bovine rhodopsin, the first GPCR to have its 
structure solved by X-ray crystallography, was 2.8 Å.25 This was quite the milestone at the time, 
though its relative abundance and stability probably greatly facilitated crystallization. With all the 
advances of GPCR structural biology, one would think that the resolution would improve overall, 
even slightly, through time. Though this is true only for some cases, the overall trend has remained 
approximately the same on average up until now (Figure 2.5A). It is noted though, while Cryo-
EM structures tend to have lower resolution in general, the 9 structures currently solved by this 
method have not contributed greatly to diminishing the average. In fact, the resolution of the 
structures range from 3.3 – 4.5 Å, which is quite an achievement given the technique’s earlier 
limitations in resolution.26 Starting in 2007, the number of GPCR structures solved with stabilizing 
point mutations has on average grown over the years (Figure 2.5B). This is likely due to its 
necessity because of challenges in the crystallography of certain GPCRs, as other unexplored 
Figure 2.4 - Percentage of Structures per GPCR Classes or Fusion Proteins by Year. (A) Starting in 2000, only structures for 
Class A GPCRs were solved until 2013, when the first structures of Class B and F GPCRs were unveiled. (B) In 2007, fusion 
proteins were added to GPCR constructs in order to increase crystallographic contacts. A popular choice was lysozyme 
initially, but soluble cytochrome b562 quickly became a recent favorite. Note that no structures were solved in 2009. 
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targets are being addressed. An extreme example of this would be the neurotensin receptor 1 (PDB: 
4BV0/4BWB), of which two structures had greater than 20 point mutations resulting from directed 
evolution.27 Regardless, the trend appears to be target dependent, as numerous GPCR structures 
have also recently been solved without any mutations. 
 
 
3.2 Browsing GPCR-EXP 
GPCR-EXP was developed to provide the user with an intuitive web interface for browsing GPCR 
structural data, which is divided into experimentally-solved structures and predicted structures. 
We designed the database to allow the access of GPCR structure-related data as fluid as possible. 
As opposed to going through numerous menus, pages, and options for one PDB structure, an 
integrated information set can be accessed in GPCR-EXP with minimal hassle. 
 
3.2.1 Experimentally-Solved Structures 
All experimentally-solved GPCR structures are arranged in a sortable table, which includes the 
following data: 1) PDB ID, 2) UniProt ID with species, 3) method used to solve the structure, 4) 
resolution (if applicable), 5) release date, and 6) reference with PubMed ID. The user can browse 
all structures in a single table or by class. The former method is useful for checking the latest 
GPCRs or sorting structures by resolution, while the latter method allows for a more controlled 
browsing experience.  
 
If browsing by class, the structures of each GPCR class are stratified into tables grouped by GPCR 
name. For example, the 5-hydroxytryptamine receptor 2C has two solved structures (Figure 2.6A). 
Figure 2.5 -  Structure Resolution and Number of Mutations by Year. (A) The overall resolution of GPCR structures has 
remained approximately the same, while (B) the overall number of mutations used per structure has increased. 
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By clicking on the GPCR structure thumbnail, users will be directed to a popup page that includes 
further data about the structure, such as mutations, fusion/associated proteins, and ligands. A link 
to our in-house GPCR-ligand database, GLASS,28 provides a more comprehensive set of 
pharmacological data corresponding to the user’s GPCR of interest. Moreover, an embedded 
structure viewer displays the processed structure, along with any applicable crystallographic 
ligands. For convenience, PDB files of the original structure, GPCR-only structure, or ligands can 
also be downloaded with a single click from the table. Additionally, there are GPCR-specific 
services that can be accessed through various popup pages. First, the user can view pre-superposed 
structures of a GPCR of interest by clicking ‘Overlay Structures’ (Figure 2.6B). Second, any small 
molecule or peptide ligands associated with a structure can be seen by clicking on ‘Display 
Ligands’ (Figure 2.6C). Third, users can click ‘Download Structures’, which will lead to a popup 
page allowing the users to customize the structures they wish to download. This feature will be 
Figure 2.6 - Experimentally-Solved GPCR Structures on GPCR-EXP. The 5-hydroxytryptamine receptor 2C is used here as 
an example. (A) Structural data is shown in a sortable table. (B) Clicking on ‘Overlay Structures’ will allow the user to view 
superposed structures, while (C) clicking on ‘Display Ligands’ will pull up and display any associated crystallographic ligands. 
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important for users interested in examining structures of interest in more details with advanced 
structure visualization software.  
 
 
3.2.2 Predicted Structures 
GPCR-I-TASSER was run to generate structure models for 1,076 GPCRs from the human genome. 
Like the experimentally-solved structures, tables for these structures are also sortable and contain 
the following data: 1) UniProt ID, 2) GPCR name, 3) C-score of the best structure model, 4) 
estimated TM-score, and 5) estimated RMSD. The user can browse all structures in one table or 
by class. If browsing by all structures, two additional columns (family / subfamily) are provided 
for reference. Class A GPCRs are stratified by subfamily, and an example with the acetylcholine 
receptors is given in Figure 2.7A. On the contrary, each of the non-Class A GPCRs are grouped 
into their respective tables because they represent a minority of GPCRs.  
 
Figure 2.7 - Predicted GPCR Structures on GPCR-EXP.  The acetylcholine receptors are used here as an example. (A) 
Structural data is shown in a sortable table. Clicking on ‘GPCR-I-TASSER’ or ‘COACH’ will provide the user with 
detailed information on the predicted structure and predicting binding site, respectively. (A) In the former, the user can 
view models (top-ranked model shown) . (B) In the latter, the user can select and view a predicted binding site of 
interest. The blue surface represents the predicted binding site, while the red surface is a possible binding ligand. 
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Detailed information on a structure model of interest can be accessed by clicking on the ‘GPCR-
I-TASSER’ button. This provides various predictions alongside the structure, such as secondary 
structure, solvent accessibility, normalized B-factor, and local accuracy. The top 10 templates used 
by GPCR-I-TASSER and associated statistics are also given, while the top 5 models are available 
for viewing and download. The top-ranked model is shown for muscarinic acetylcholine receptor 
M1 as an example in Figure 2.7B. Additionally, a visual assessment of the local structure quality 
of the model is given by ResQ,29 an algorithm which makes predictions about residue-level model 
quality and B-factor estimations through the combination of sequence- and structure-based 
profiling. Alongside the structure models, binding site predictions from COACH12-13 based on the 
top-ranked models are also shown, where detailed information can be retrieved by clicking on the 
‘COACH’ button. Here, the predicted binding sites from COACH and each of its component 
methods are displayed along with all related statistics from the prediction. Furthermore, the 
binding pocket can be visually examined from the GPCR on the web interface (Figure 2.7C).  
 
3.3 Downloading GPCR-EXP 
All data compiled and processed from PDB are freely available for download on the web server. 
Bulk downloads include a TSV file of all data pertaining to experimentally-solved GPCR 
structures, as well as a text file containing detailed statistics. Moreover, the following PDB file 
compilations are also available for download: 1) all original PDB files, 2) GPCR structures 
modified to contain single chain, 3) superposed GPCRs along with respective ligands, 4) GPCR 
fragments, and 5) predicted GPCR structures from human genome.  
 
3.4 Maintenance of GPCR-EXP 
The update pipeline for the experimentally-solved GPCRs is almost fully automated, apart from 
the manual inspection of ligands. As such, updating the database is streamlined and requires 
minimal oversight for implementation. As of the time of writing, we are running weekly updates 
for this data. On the other hand, GPCR-I-TASSER and COACH predictions on all GPCRs from 
the human genome are only updated annually due to its high computational cost.  
 
4. Summary 
We have developed a database, GPCR-EXP, which combines data for experimental and predicted 
structures related to GPCRs. Overall, GPCR-EXP contains the following unique features: 
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(1) Semi-manual curation of the data allows for a quick and high-quality update of the database 
content. Most of the updating process is implemented through a custom script, while the 
ligand data is manually cross-examined with the literature using PubMed, in order to avoid 
the inclusion of ions, detergents, and other non-pharmacological ligands.  
(2) Computational models from cutting-edge methods are provided for the GPCRs that do not 
have experimental structure available. In particular, GPCR-I-TASSER creates structural 
models using iterative fragment assembly, which allows reliably modeling on some of the 
distant-homologous protein targets, while COACH generates high-quality binding site 
predictions. 
(3) Given the critical importance of the quality information to the biomedical users, a confidence 
scoring system is given to estimate the global quality of all the predicted GPCR-I-TASSER 
models. Meanwhile, a reliable B-factor modeling method,29 which was validated in the last 
CASP experiment,30 is used to estimate the accuracy of the local structures. These model 
quality annotations are important in better assisting the use of the predicted models for users 
working in the biomedical sciences. 
(4) All experimental PDB structures with a full transmembrane domain have been preprocessed 
to have a single chain. Fusion proteins (such as lysozyme) have been programmatically 
removed as well.  
(5) Experimental structures of the same GPCR have been pre-superposed and are made viewable 
on the web page, as well as downloadable. This feature will be useful for researchers 
interested in studying differences in the binding pocket of different ligand-bound complexes, 
as well as between active and inactive state structures. 
(6) All ligand data have been curated and are viewable on the web page. Additionally, PDB files 
of the crystallographic poses are provided. 
(7) All data are freely available for download. Batch PDB files of all the original structures, 
single chain structures, and superposed structures are provided with the detailed statistics 
and general data. 
(8) GPCR-EXP is updated weekly to account for the increasing frequency of release of new 
GPCR structures. 
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In conclusion, all of these features address the aforementioned issues brought up earlier. With 
semi-manual curation of data, weekly updates are possible because of the programmatic nature of 
process, while human error is significantly cut down. Additionally, the inclusion of a user-friendly 
interface allows researchers to easily access whatever data is desired in an expedient fashion. For 
these reasons, we believe that GPCR-EXP will be an invaluable resource to researchers in drug 
discovery. Interestingly, GPCR-EXP was originally conceived in 2015 and has managed to garner 
mentions in several scientific publications31-36 from biomedical users, despite the manuscript 
describing the database yet to be published. With the latest, more-comprehensive version of our 
database, we are confident to have a lasting impact in GPCR research, and hence in drug discovery 
on the whole. 
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CHAPTER 3.  
GLASS: A Comprehensive Database for Experimentally-Validated  
GPCR-Ligand Associations1 
 
1. Introduction 
G protein-coupled receptors (GPCR) represent one of the largest families of transmembrane 
proteins that bind extracellular molecules and activate intracellular signal transduction pathways, 
which mediate many physiological functions through their interaction with heterotrimeric G 
proteins. Many human diseases, including cancer and diabetes, have been found to be associated 
with the malfunction of the biological roles of GPCRs.2 Currently, approximately 30-50% of drugs 
on the market target GPCRs, making them one of the most attractive membrane receptors for drug 
development.3-4 While experiment-based assays for novel chemical compounds remain the 
standard procedure for drug discovery, in silico screening is gaining increasing acceptance as an 
important complementary method to narrow down the drug searching scope and to guide 
experimental design. Another advantage of the computational approach is due to its high speed 
and low cost, which enables high-throughput and large-scale database screening.5  
 
Both the experimental and computational drug discovery approaches rely on existing GPCR-ligand 
experimental data to provide insight for screening and selecting new drugs. A variety of GPCR-
orientated databases, such as GPCRDB,6 TinyGRAP,7 GPCR-OKB,8 GDD,9 and GPCR-RD,10 
have been developed, which generated important impacts on various molecule-level studies on the 
elucidation of GPCR structure and function. 
 
There are however very few databases that can provide comprehensive resources for GPCR-ligand 
interactions that are essential in assisting GPCR virtual screening studies.11-13 One difficulty in 
                                                          
1 This chapter was adapted from a previously-published work in Bioinformatics, entitled “GLASS: a comprehensive 
database for experimentally validated GPCR-ligand associations” by WKB Chan, H Zhang, J Yang, JR Brender, J Hur, 
A Özgür, and Yang Zhang. WKB Chan and H Zhang shared co-authorship in the study.  
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developing such databases is that the GPCRs can be associated with a large number of ligands in 
various binding affinities, and the GPCR-ligand association data in many chemical libraries are 
often mixed with various false-positives. A collection of GPCR-ligand associations with stringent 
experimental validations and careful human curation is essential to ensure the quality of the 
datasets. Second, with the success of the sequencing and structural genomics projects, the number 
of available GPCR and ligand interactions increase rapidly. But most of the new studies are 
scattered in a wide spread of publications and archives, which makes it difficult to keep the 
databases up to date. For example, GLIDA14 was a useful GPCR-ligand binding database designed 
for chemical genomic drug discovery; but it has ceased updates to its server since October 2010. 
The current GLIDA library contains around 39,000 GPCR-ligand entries, whereas the amount of 
unique GPCR-ligand interactions available in the literature in our estimation is above 500,000. 
The missing of such a substantial amount of new data significantly degrades the usefulness of the 
databases to the experimental and computational drug discovery studies. 
 
In this study, we have developed a new GPCR-ligand association (GLASS) database for use as a 
general platform in assisting GPCR-related drug screening studies. Drawing from multiple primary 
data sources, GLASS focuses on a comprehensive and yet precise collection of the experimentally-
validated GPCR-ligand interactions with strong affinities. All the GPCR-ligand association data 
are manually-curated and made freely-available to the community. 
 
2. Data and Methods 
The GPCR-ligand association data in GLASS consist of two major resources. The first resource 
consists of five primary pharmacological datasets from ChEMBL,15 BindingDB,16 IUPHAR,17 
DrugBank,18 and PDSP,19 which contain various bioactive ligand and protein interaction data. A 
flowchart of the construction of GLASS is depicted in Figure 3.1. 
 
2.1. Database Recombination Pipeline 
A list of all reviewed UniProt IDs pertaining to GPCRs was first collected from UniProtKB.20 Data 
relevant to each GPCR, such as species, gene name, and primary sequence, were simultaneously 
extracted. We used a combination of synonymous GPCR names from IUPHAR and UniProtKB. 
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In the second step, flat line databases were downloaded from the pharmacological databases of 
ChEMBL, BindingDB, IUPHAR, DrugBank, and PDSP. Data entries were filtered only for 
GPCR-related ones using UniProt ID and compiled together. The ligands without chemical 
identifiers were eliminated. Meanwhile, the statistical analysis of the distributions among the Ki, 
Kd, IC50, and EC50 values revealed that the majority (>95%) of the experimental ligand-GPCR 
associations have the activity values below 10 µM. Thus, an activity filter was implemented, i.e. 
the entries with a Ki, Kd, IC50, and EC50 higher than 10 µM were designated as inactive 
compounds, in order to sieve out weak and suspicious GPCR-ligand associations. Once an entry 
passes all criteria, records on the pharmacological data (e.g. ligand activities), the references to the 
original literature of study, and the chemical identifiers such as SMILES or InChI, are collected 
from the original pharmacological databases. Overall, the compiled compound files for both active 
and inactive compounds were generated and included as download for users.  
 
Figure 3.1 - Flowchart for the Construction of GLASS Database. 
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2.2. Architecture of the GLASS Library 
The GLASS database was built using MySQL, while the Internet webpage was augmented with a 
combination of Perl and Python CGI scripts to facilitate the communication of the interfaces with 
the MySQL database. 
For each GPCR-ligand association, relevant chemical information, such as XlogP, molecular 
weight, hydrogen bond acceptor and donor, 2D structure image, synonyms, and IUPAC name, 
were extracted from PubChem using the compound identifier (CID) of each ligand via their 
Chemical Identifier Exchange service. The 3D SDF files were generated from respective canonical 
SMILES strings using Open Babel.21 
 
For the GPCRs from the human genome, the associated conditions and diseases from experiments 
were compiled from TTD22 when available. The 3D structure information is provided for each 
GPCR by cross-linking to the PDB when the experimental structures are available; otherwise, a 
link is provided to the GPCR-HGmod,23 a comprehensive human GPCR structure database with 
all models constructed by the GPCR-I-TASSER algorithm assisted with the mutagenesis 
experimental restraints. A confidence score is provided for each of the GPCR structure models to 
calibrate the quality. An NGL Viewer image is created for each GPCR to allow users to view the 
3D structure of the receptor. 
 
To facilitate comparative interaction studies, GLASS provides an interactive search engine to 
collect homology ligand/compounds through either substructure or chemical similarity. Using the 
JSME molecular editor,24 users are allowed to draw a chemical structure of the compounds, which 
is then converted into a SMILES string. Subsequently, it is transferred to Open Babel for either a 
substructure or similarity search against the indexed ligands. An SDF file is pre-created containing 
all ligand indexes in order to expedite the searching process. For the chemical similarity search, 
users are able to select the Tanimoto coefficient cutoffs. The resultant ligands are returned as 
SMILES strings. Finally, the SMILES strings are used as probes to search against the database in 
order to collect homologous ligands, which are returned as images of the chemical structure and 
their names. Tanimoto coefficients are returned, as well, if the similarity search was selected. 
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3. Results  
3.1 GLASS in Numbers 
As of the time of writing, GLASS contains 994,751 GPCR-ligand entries, collected from multiple 
sources of experiments. Some associations appear more than once in different experiments. After 
removing the redundant entries, there are 549,792 unique associations each containing a species-
specific GPCR paired with an interacting ligand (444,959 unique associations remain if removing 
the redundancy across species and accounting for orthologues). 
 
A total of 3,056 GPCR entries in GLASS were extracted from UniProt,20 where 733 GPCRs have 
at least one ligand associations. The other 2,323 GPCR entries have no ligand associated data in 
the experiment literature as of the present time. Among the GPCR’s with ligand associations, there 
are approximately 750 different types of ligand/compound associations per receptor on average; 
but the median value is only 77 due to the fact that several receptor families have a dominantly 
high number of ligand associations (see below). The total number of unique ligands in GLASS is 
335,040. A summary of the current GLASS database is presented in Table 3.1. 
 
Most of the ligand asso ciations in GLASS are skewed towards the Class-A rhodopsin-like family 
of GPCRs, which makes up approximately 80% of the association data (Figure 3.2). The top four 
receptors in the rhodopsin-like family, all of which have more than 65,000 ligand associations, are 
from serotonin, adenine and adenosine nucleotide, opioid, and dopamine receptors. These 
Figure 3.2 - Distribution of GPCR-Ligand Data in 
GLASS by Family. All values presented as percentage of 
total. Fungal, cyclic AMP, slime mold, OA, and T2R 
receptors, which have insufficient (<10 entries) or no 
data, were excluded from the plot. 
 
Table 3.1 - Summary of GLASS Database 
 
Type of entry Number of entries 
All GPCRs 3,056 
        With ligand association 733 
        Without ligand association 2,323 
Unique ligands 335,040 
        Drug-like ligands 238,027 
All GPCR-ligand associations 994,751 
        Unique associations 549,792 
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Figure 3.3 - Histogram of Ligand Associations with GPCRs in the Class A (Rhodopsin-like) Family. The figure only 
displays the GPCRs with at least one ligand associations. 
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receptors also represent the set of the most popularly studied GPCRs in literature due to their 
importance in pharmaceutical applications and research. A histogram of the ligand associations 
for the entire Class-A family is shown in Figure 3.3. 
 
 
The non-rhodopsin-like families of GPCRs constitute a far lesser proportion of ligand associations. 
Nevertheless, the human glucagon-like peptide 1 receptor from the Class-B secretin family 
contains the most abundant GPCR-ligand associations among all the human GPCRs, containing 
over 100,000 entries. The other non-rhodopsin-like GPCRs with more than 2,000 GPCR-ligand 
Figure 3.4 - Histogram of Ligand Associations with GPCRs in the Class B (Secretin) Family. The figure only displays the 
GPCRs with at least one ligand associations. 
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associations are the metabotropic glutamate group of receptors from the Class-C metabotropic 
glutamate/pheromone family. There are only two members (UniProt ID:  Q88935 and P56726) 
from the Class-F family that have associated experimental data, while little to no GPCR-ligand 
associations are found for the GPCRs from the fungal mating pheromone (Class-D), cyclic AMP 
Figure 3.5 - Histogram of Ligand Associations with GPCRs in the Class C (Metabotropic Glutamate/Pheromone) Family. 
The figure only displays the GPCRs with at least one ligand associations. 
 
Figure 3.6 - Histogram of Ligand Associations with GPCRs in the Class F (Frizzled /Smoothened) Family. The figure only 
displays the GPCRs with at least one ligand associations. 
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(Class-E), slime mold, ocular albinism (OA), and taste receptor (T2R) families. Figures 3.4-3.6 
list the detailed data distributions of ligand associations for Class-B, C, and F families. This highly 
uneven ligand association distribution explains the reason that the median number of ligands per 
receptor is much lower than the average. 
 
 
 
 
3.2 Survey of Experimental Data 
All experimental data related to Kd, Ki, IC50, and EC50, some common experimental measures in 
pharmacology, were collected for analysis and summarized in Figure 3.7. All four of these 
followed an approximately normal distribution when transformed to their negative log form and 
conformed to expectations. Typical cutoffs of 10 µM were used as activity filters for GLASS 
database in creating a filtered chemical subset. However, a cutoff of 20 µM for IC50 and EC50 was 
Figure 3.7 - Activity Distributions of Ligands from GLASS Database. Pharmacological data covered include (A.) Kd, (B.) Ki, 
(C.)  IC50, and (D.) EC50. All experimental values are converted to the negative log form. Thus, pKd = -logKd. The dashed red line 
indicates the activity cutoff used for the creation of ligand sets in MAGELLAN, which was 10 µM for Ki and Kd and 20 µM for 
IC50 and EC50. 
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used in the following chapter with MAGELLAN and will be explained in there. Overall, there was 
only a small reduction in the amount of data after filtration. The most shocking revelation while 
surveying the publicly-available experimental data was the inconsistencies between studies. Many 
experimental values for the same ligand and receptor were found to be over 2 orders of magnitude 
different from one another (Figure 3.8). This is consistent with a previous study on IC50 data from 
ChEMBL.25 The variation is understandable for measures such as EC50 and IC50 because they are 
assay specific and comparable only under certain conditions. However, for constants like Kd and 
Ki, the disagreements are deeply troubling and potentially reflective of the problem of 
irreproducibility in science.  
 
 
 
 
Figure 3.8 - Pairs of Activity Data from GLASS Database. Pharmacological data covered include (A.) Kd, (B.) Ki, (C.)  
IC50, and (D.) EC50. Non-redundant pairs of experimental values are shown between all GPCRs and their ligands. All 
experimental values are converted to the negative log form. Thus, pKd = -logKd. The outer dashed lines represent a 2.5 log 
unit threshold.  
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3.3. Database Features 
The GLASS database is updated every month, and all data are made freely available at: 
http://zhanglab.ccmb.med.umich.edu/ GLASS/. Three features have been developed for searching, 
browsing, or downloading of the GPCR-ligand association data in GLASS, as shown in Figure 
3.8, which are outlined in the following. 
 
3.3.1. Searching GLASS 
An efficient search function is essential to the development of biomedical databases. GLASS 
provides three options on the home page for searching the database based on three types of queries: 
(1) GPCR-based, (2) ligand-based, and (3) GPCR-ligand-based. Users can choose these options 
by selecting the radio button of interest before or after typing the desired input (Figure 3.8).  
 
 
 
Figure 3.8 - A screen shot of the GLASS homepage showing options for searching, browsing, and downloading of database-
related data. 
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Using the GPCR-based search, users can search for a GPCR of interest using a variety of inputs, 
including UniProt ID, gene name, or associated medical conditions. Clicking on the ‘Search’ 
button takes the user to a page listing all GPCRs that match the query; clicking and following the 
link of the GPCR of interest will bring the user to a detailed page with GPCR-related information, 
including GPCR name, species, gene name, synonyms, associated diseases, primary sequence and 
its length, atomic structural model, and database identifiers. All ligands that are associated with 
Figure 3.10 - Illustration of the output page for the ligand-
based search on GLASS. The ligand shown is prenalterol, one 
of the associationed ligands for the human β2 adrenergic 
receptor in Figure 5. GPCRs bound with prenalterol are listed 
at the bottom of the page. 
 
Figure 3.9 - Illustration of the output of GPCR-based 
search from GLASS. This example is from the human 
β2 adrenergic receptor, where ligands associated with 
the receptor are listed at the bottom of the page. The 3D 
structure shown was from the PDB entry solved by 
Cherezov et al.1 
64 
 
the GPCR are listed at the bottom of the page. Figure 3.9 presents an example of output of the 
GPCR-based search from the human β2 adrenergic receptor. 
 
The ligand-based search requires knowledge of the name, chemical identifier, or PubChem ID of 
the ligand of interest. Clicking on the ‘Search’ button will bring the user to a page of results of all 
ligands matching the query. Clicking and following the link of the ligand of interest will bring up 
a detailed page with the ligand name, molecular formula, IUPAC name, synonyms, physico-
chemical properties, chemical identifiers, database identifiers, 2D chemical structure, and a list of 
GPCR targets with experimental data. An example output involving the ligand, prenalterol, is 
shown in Figure 3.10, where all GPCRs that bind with the ligand are listed at the bottom of the 
page. 
 
Figure 3.11 - Searching GLASS database for ligands using either the substructure similarity (Left Panel) or chemical similarity 
(Right Panel). The users first specify the ligand by importing a MOL or SDF file or draw the molecule into the JSME molecular 
editor. In this example, morphine is the query molecule. By clicking on the ‘Fetch Compounds’ button, the substructure search 
pipeline will look for ligands that have the molecule that the users specified as part of its chemical structure; the chemical 
similarity search pipeline will return all ligands that are at least 70% chemically identical to the query (the cutoff is adjustable). 
While the ligand name and chemical structure are provided for the users in both searches, Tanimoto coefficients are seen only 
with the chemical similarity search. 
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Although the GPCR-ligand association information can be retrieved from the GPCR- and ligand-
based searches, GLASS provides a third GPCR-ligand-based search option if the respective 
GLASS ID of the interaction is known. In the above example, the GLASS ID of the human β2 
adrenergic receptor and prenalterol association is ‘8792’. By searching on ‘8792’, the users will 
be brought to a page containing GPCR and ligand information, as well as experimental binding 
affinity data. In this example, the free energy of binding was reported to be 9.76 kcal/mol from the 
reference with the PubMed ID 24063433. 
 
In addition to the ligand-, GPCR- and ligand-GPCR-based searching options, GLASS provides a 
target-based search for users who wish to locate a particular ligand by either chemical similarity 
or match of substructure (Figure 3.11). Using the JSME chemical editor, the user can manually 
draw a ligand of interest or import a MOL or SDF file. Substructure search queries should be for 
the ligands of sufficient chemical complexity, as it would otherwise match too many ligands and 
result in an unreasonably long search. Searching by chemical similarity, there are options to select 
for a percentage cutoff. Results are returned with respective ligands and 2D chemical structure 
images; Tanimoto coefficients are also provided for similarity searches. All ligands found can be 
downloaded in SDF file format. An example to search homologies of morphine is illustrated in 
Figure 3.10.  
 
 
3.3.2. Browsing GLASS 
A comprehensive list of GPCRs and ligands from GLASS is provided on the home page to enable 
browsing of all entries in bulk. Additionally, the user can also browse all GPCRs as sorted by their 
respective families as designated by UniProt.20 According to this schema, the rhodopsin-like 
family GPCR entries are further divided into the level of sub-families due to the high volume of 
entries, while the rest of the families remain in one level. 
 
3.3.3. Downloading GLASS 
Tables of GPCR, GPCR-ligand, and ligand data are all made available for download in TSV file 
format. A zipped SDF file of all GLASS ligands in 3D format is available and ready for use in 
molecular docking experiments; physicochemical properties and molecular descriptors are 
included within the property tags for the user’s convenience. 
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4. Summary 
We have developed a new database, GLASS, which encompasses a wide breadth of GPCR-related 
pharmacological data, gathered from a multitude of data sources. GLASS contains over ten times 
more ligand and GPCR-ligand interaction data than the leading databases, which makes GLASS 
the most comprehensive and up-to-date GPCR-ligand association repository in the field. It is 
however the novel sets of data collection and feature setting, rather than the sheer amount of data, 
which makes GLASS database unique. 
 
The current structure of GLASS database has been made to retain the majority of GPCR-ligand 
pharmacological data after some definitive filters to rule out false positives; this gives users options 
to choose proper cutoff values for certain experimental parameters, such as binding constants. This 
will avoid any subjective pre-cutoffs that limit user’s flexibility. Certain GPCR-ligand databases, 
such as GLIDA,14 only give a list of ligands with biological activities as opposed to experimental 
parameters. For example, a ligand could be designated as an agonist for a GPCR, but we are left 
unaware of how it came to be as such. The pre-cutoff setting makes it difficult to customize ligand 
datasets by experimental values for analysis. GLASS database was designed to ensure all of its 
extracted data available for user manipulation. The presence of this option means that analyses can 
be performed on individual GPCRs to elucidate their ligand preferences based on various cutoff 
values. 
 
One of the major difficulties in studying GPCR-ligand association stems from the lack of 3D 
structure of the receptors due to the notorious recalcitrance to crystallization.26 Currently, GLASS 
has integrated X-ray crystal structures for numerous GPCRs from the PDB library and predicted 
models by GPCR-I-TASSER for all 1,073 human GPCRs from GPCR-EXP database 
(http://zhanglab.ccmb.med.umich.edu/GPCR-EXP/). In the next step, we are extending GPCR-I-
TASSER to generate atomic structure models for the rest of 2,020 GPCRs from other species. 
Meanwhile, we will extend the cutting-edge ligand binding prediction approaches, including 
COFACTOR27 and COACH28, to deduce the ligand-binding sites of all GPCRs based on the 
GPCR-I-TASSER models. The high-resolution 3D structure and ligand-binding prediction data 
will provide useful insights to the physical landscape of the GPCR-ligand associations. 
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One of the focuses of GLASS is to provide references to various experimental and computational 
virtual screening studies. For instance, an important approach to GPCR virtual screening is to 
collect ligand profiles from homologous ligand-GPCR interactions,13 where the completeness of 
the ligand-GPCR associations in GLASS will be essential to increase the sensitivity and 
recognition power of the ligand profiles. With its comprehensive coverage of datasets and 
consistent updates of data, we expect that GLASS become an important primary GPCR resource 
and impart its usefulness in many other biomedical studies, including in silico GPCR drug 
discovery, GPCR de-orphanization, and functional annotation. 
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CHAPTER 4.  
MAGELLAN: Incorporation of Sequence and Structure Information in a Ligand-Profile 
Based Virtual Screen for Human Class-A G Protein-Coupled Receptors 
 
 
 
1. Introduction 
G protein-coupled receptors (GPCR) are a large superfamily of transmembrane receptors 
responsible for cellular signal transductions. The malfunction of the receptors is the cause of a 
wide array of pathologies, such as cancer and diabetes.1-2 Consequently, GPCRs are among the 
most clinically-studied targets in drug discovery. A detailed analysis of the DrugBank shows that 
23% of the 2,276 FDA-approved drugs on the market, including both small molecules and 
biologics, target GPCRs, while out of other 2,641 drugs that are under some form of clinical trial, 
8% target GPCRs. Overall, GPCRs represent targets of 15% of all drugs that are either approved 
and investigational (Figure 1). 
Figure 4.1 - DrugBank Statistics for GPCRs. Percentage of small molecule and biotech drugs shown for 
GPCR and non-GPCR targets under the groups of (A) approved, (B) investigational, and (C) total drugs.  
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A mainstay in drug development is high-throughput screening (HTS), a technique biochemically 
assaying a pharmacological target against the candidate compounds. However, HTS is usually 
costly and laborious, where various in silico approaches have found useful to assist and 
complement HTS.3 There are two general approaches that are commonly employed in the 
computer-aided drug screening: ligand-based and receptor-based virtual screening. In the former, 
knowledge of what ligands the receptor targets tend to bind is used to develop a model for drug 
screening,4-5 while the latter utilizes structural information of the receptors to predict ligand-
binding affinity, normally through docking.6-7 Although structure-based approaches are typically 
very computationally expensive and can take a long time to run, they can be very useful when the 
structure of the receptor is known, producing results that may be biochemically relevant; on the 
other hand, ligand-based approaches are usually very fast, but they tend to be biased towards 
ligands that are currently known.8 
 
However, both structure and ligand-based approaches require some sort of information, either 
known active ligands or a structure, and this may not be available for a drug target of interest. The 
orphan GPCRs are one such example, many of which lack known endogenous ligands.9 In this 
regard, chemical genomics approaches are often applied to infer ligand binding information, based 
on the assumption that similar receptors bind similar ligands.10 One of the earliest applications of 
the idea was with the algorithm, FINDSITE, which uses ligand information from structurally-
homologous receptors found through fold-recognition in a ligand-based virtual screen.11-12 
Another more-recent algorithm is PoLi, developed by the same lab, which looks for similar protein 
receptors by performing binding pocket structure comparison between the query and targets, 
followed by a ligand-based screening search.5  
 
Though structure is generally considered to be more conserved than sequence in evolution, relying 
solely on structural similarities can result in high false positives in ligand information deduction, 
as receptors of similar structures often bind with different ligands. In particular, experimental 
structures are not always available for many medically-relevant target proteins, where low-
resolution models would have to be generated for the target receptors; this would further impact 
the accuracy and specificity of the structure-based ligand inferences. This is true especially for the 
case of GPCR families, which all have similar global folds but different local structure at the 
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binding sites.13 Moreover, the majority of the structure-based approaches rely on selecting 
homologous proteins and their respective ligand sets from the Protein Data Bank (PDB);14 however, 
pharmacological data are often found in low quantities within the PDB. Currently, there are many 
more proteins with known pharmacological data than those with known structures. The largest 
sources of publicly-available ligand data reside in various manually curated databases, such as 
ChEMBL,15 BindingDB,16 and GLASS (for GPCRs).17 Using the wealth of information from such 
resources should help enhance the accuracy of the ligand-based approaches. 
 
In this study, we present a novel ligand-profile based virtual screening approach, MAGELLAN 
(standing for Michigan G protein-coupled receptor ligand-based virtual screen), specifically 
designed for G protein-coupled receptors. To enhance the reliability and robustness of ligand-
based screening approach, multiple methods, utilizing both structure- and sequence-based 
alignments, are employed for detecting heterogeneous receptor homologies, from which consensus 
ligand profiles are created for the next step of virtual screening. To examine the strength and 
weakness of the pipeline, large-scale tests are performed on 224 representative Class A GPCRs, 
which are carefully controlled with various component and state-of-the-art methods. Here, Class 
A GPCRs were selected as the focus mainly because of their high diversities in structure and 
function and clinical importance in drug discovery. Moreover, the conserved transmembrane 
domains of these receptors make it an ideal case for examining the sequence- and structure-based 
alignment pipelines. An on-line MAGELLAN webserver, together with the virtual screening 
results for all human GPCRs and the filtered ligand sets, are available and downloadable at 
https://zhanglab.ccmb.med.umich.edu/MAGELLAN. 
 
2. Methods 
The virtual screening process of MAGELLAN consists of three distinct stages: 1) GPCR alignment 
and selection, 2) ligand profile construction, and 3) virtual screening. The flowchart of the 
MAGELLAN pipeline is depicted in Figure 2, which starts with a single primary sequence of the 
target (or query) GPCR in FASTA format, where the output consists of a list of predicted ligands 
bound with the target. 
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2.1 Construction of Ligand-GPCR Association Library 
The central assumption of MAGELLAN is that similar receptors bind similar ligands.10 For this 
purpose, a comprehensive library of GPCR-ligand associations is constructed from the GLASS 
database 17. Here, only experimental values of Ki, Kd, IC50, and EC50 were used. In case that 
multiple experimental values exist for the same GPCR-ligand pair from different studies, the 
Figure 4.2 - MAGELLAN pipeline 
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median was taken as the representative value to avoid outliers. To filter out inactive ligands, a 
common threshold of 10 µM is used for both Ki and Kd values. However, a threshold of 20 µM 
was set for IC50 and EC50, justified by a previous study that found a Ki-IC50 conversion factor of 2 
to be suitable.18 This relatively loose criterion could account for variability in assay conditions, 
inherent in the types of experiments used to determine these values. After filtration, the library 
contains 238,108 GPCR-ligand associations attached with 644 GPCRs.  
 
2.2 Detection of Homologous GPCRs 
The first stage of MAGELLAN is to select homologous GPCRs, in order to construct a predictive 
model for what the target GPCR would potentially bind. Five complementary algorithms, 
including TM-align,19 PPS-Align,20 BLAST,21 PSI-BLAST22 and BindRes, are extended to detect 
analogous GPCRs, where the first two are structure based and the other three are built on sequence 
and sequence-profile comparisons. 
 
In the first GPCR detection pipeline, TM-align19 is used to align the global structures of query to 
template GPCRs. To obtain a structure model of the query GPCR, its query sequence is submitted 
to GPCR-I-TASSER, which was designed to create full-length GPCR structures by reassembling 
the structural fragments from threading through replica-exchange Monte Carlo simulations.23 The 
resulting structure models are then compared against the GPCRs in the pre-compiled GPCR-ligand 
library, where the structures are also generated with GPCR-I-TASSER. The resultant GPCRs 
detected by TM-align are scored by: 
𝑆𝑇𝑀𝑎𝑙𝑖𝑔𝑛 =
2
1 + 𝑒−(0.2T+f(0.4S + 0.3E + 0.2𝐽) + 𝑅)2
− 1                                 (1) 
Here, 𝑇 =
1
𝐿
∑
1
1+(
𝑑𝑖
𝑑0
)
2
𝐿𝑎𝑙𝑖
𝑖  is the TM-score to measure the global structure similarity of the query 
and template models, where 𝐿 is the length of the query sequence, 𝐿𝑎𝑙𝑖 is the number of aligned 
residues by TM-align, 𝑑𝑖 is the distance of ith pair of aligned residues between query and template 
and 𝑑0 = 1.24√𝐿 − 15
3
− 1.8 is the scale factor; 𝑓 = 𝑚/𝑛 is the fraction of the aligned residues 
in the binding pocket (𝑚) normalized by the total number of binding residues (𝑛) on the template; 
𝑆 =
1
𝑛
∑
1
1+(
𝑑𝑖
𝑑0
)
2
𝑛
𝑖=1  accounts for the local structural similarity of the binding pockets between query 
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and template; 𝐸 =
1
𝑛
∑ 𝐵(𝐴𝑖
𝑞 , 𝐴𝑖
𝑡)𝑛𝑖=1  measures the evolutionary relation between the aligned 
binding residues, where 𝐵(𝐴𝑖
𝑞 , 𝐴𝑖
𝑡)  is the BLOSUM mutation score; 𝐽 =
1
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𝑎 log
𝑝𝑖
𝑎
𝑝𝑖
𝑎+𝑞𝑎
+∑ 𝑞𝑎 log
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𝑎
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 20𝑎
20
𝑎 )
𝑛
𝑖=1  is the average Jensen-Shannon divergence over the 
binding pocket, where 𝑝𝑖
𝑎 is the frequency of amino acid 𝑎 at ith column of multiple sequence 
alignment (MSA) identified by PSI-Blast for the query GPCR and 𝑞𝑎 is the background frequency; 
and R is the residue chemical similarity of the binding site residues, where Figure 4.3 provides an 
illustrative example for how the residue chemical similarity was calculated. 
 
 
Second, PPS-Align is an algorithm recently designed for sequence-order independent structure 
alignments of binding pockets.20 In this pipeline, the GPCR-I-TASSER models of query and 
template GPCRs are submitted to COACH,24 which was designed to detect ligand binding residues 
through composite sequence-profile and structure comparisons. The ligand binding pockets are 
then constructed by clustering the COACH binding-site predictions with the highest confidence 
score, which are finally aligned by PPS-Align for pocket comparisons. The GPCR templates from 
the library are scored by  
Figure 4.3 - Explanation of the Residue Chemical Similarity (RCS) Term. (A) Shown is the binary representation of the 
chemical features of aspartate. Each bit is position dependent and corresponds to one of four chemical features (H-bond donor, 
H-bond acceptor, aromatic, and aliphatic). The anionic oxygen from the carboxyl group (red box) is a H-bond acceptor, thus a 
bit is set in the second position. (B) In this simplified example, the two binding pockets are a binary representation of the 
chemical features of the aligned binding pockets produced from PPS-Align. The RCS calculation is essentially a Tanimoto 
coefficient calculation between the two bit-string representations of the binding pockets, where a is the number of bits in 
Binding Pocket 1, b is the number of bits in Binding Pocket 2, and c is the number of bits shared between the two. Here, the 
two binding pockets have a RCS of 0.2, as shown in the figure. 
75 
 
𝑆𝑃𝑃𝑆𝑎𝑙𝑖𝑔𝑛 =
2
1 + 𝑒−(𝑃𝑃𝑆 + 0.25S + 0.25𝐽 + 𝐼𝑏𝑠)
− 1                                 (2) 
where 𝑃𝑃𝑆 in [0,1] is the pocket similarity score returned by PPS-Align, 𝑆 and 𝐽 are the same as 
defined in Eq. (1), and 𝐼𝑏𝑠 is the sequence identity of the binding-site residues in the PPS-align 
aligned region between query and template GPCRs. 
 
In the third BindRes pipeline, we first parse the transmembrane (TM) domains of the query GPCR 
according to the UniProtKB/SwissProt annotation, which are then aligned with the TM domains 
of all template GPCRs in the library using Clustal Omega.25 The template GPCRs are ranked by 
𝑆𝐵𝑖𝑛𝑑𝑅𝑒𝑠 =
2
1 + 𝑒−(𝐼𝑏𝑠+𝑅+0.2𝐽)
− 1                                 (3) 
where 𝐼𝑏𝑠, 𝑅 and 𝐽 are defined similarly as in Eqs. (1-2). The calculations focus solely on the 44 
orthosteric binding site residues on the TM-domains, as specified by Gloriam et al.26 Since these 
orthosteric residues have been labelled in Ballesteros-Weinstein numbering system,27 the identities 
can be conveniently referred through the most conserved residue of each TM domain according to 
the Clustal Omega alignments. 
 
Finally, the BLAST and PSI-BLAST pipelines use the programs from the NCBI BLAST+ software 
suite (V2.2.29). For BLAST, the query GPCR sequence is matched against the GPCR templates, 
which are sorted by descending sequence identity to the query. The same is done for PSI-BLAST 
but with sequence-profile alignment, where the profiles were collected with 4 iterations from the 
non-redundant (NR) sequence database from NCBI under an E-value cutoff of 0.001. The results 
are also ranked by descending sequence identity. 
 
2.3 Ligand Profile Construction and Profile-Based Virtual Screening 
Associated active ligands from the ten top-ranked GPCRs are compiled for each of the five GPCR 
alignment methods. It should be noted that all ligands are originally represented as InChI 
identifiers and keys, and converted into 1,024-bit Morgan fingerprints with a radius of 2 using 
RDKit.28  
 
To capture the most common chemotypes, the resulting ligand collections are clustered with the 
Taylor-Butina algorithm29-30 using the Chemfp Python library,31 where a Tanimoto coefficient (TC) 
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cutoff of 0.8 was used. The 40 largest GPCR clusters are selected for use in the next step of virtual 
screening. If there are fewer than 40 clusters, all of them are used. 
For a given cluster (k), a ligand profile is constructed for the query GPCR, which is represented 
by a 1024 × 𝑁𝑘 matrix, where 𝑁𝑘 is the number of non-redundant ligands in the cluster and each 
ligand has 1024-bit fingerprints taken from the ZINC12 database (Figure 3). A profile-compound 
calculation is performed through the compound library using a profile score of 
𝑃𝑟𝑆𝑘(𝑧) =
1
Nk
∑𝑤𝑖𝑇𝑖,𝑧
𝑁𝑘
𝑖=1
                                 (4) 
where 𝑇𝑖,𝑧 =
∑ 𝑏𝑖
𝑗
𝑏𝑧
𝑗1024
𝑗=1
∑ 𝑏
𝑖
𝑗
𝑏
𝑖
𝑗1024
𝑗=1 +∑ 𝑏𝑧
𝑗
𝑏𝑧
𝑗1024
𝑗=1 −∑ 𝑏𝑖
𝑗
𝑏𝑧
𝑗1024
𝑗=1
 is the Tanimoto coefficient between the ith ligand and 
the zth compound in the database. Here, 𝑏𝑖
𝑗
 and 𝑏𝑧
𝑗
 are the bits in the ith and the zth compounds, 
respectively. 𝑤𝑖 =
1
𝑀𝑖
∑ 𝑆𝑚(𝑖)
𝑀𝑖
𝑚=1  is the weighting factor for ligand i, where 𝑆𝑚(𝑖) is the scoring 
function of mth alignment method as defined in Eqs. (1-3) and 𝑀𝑖 is the total number of methods 
that identifies the ith ligand (Figure 4.4). 
 
For each cluster (k), each 𝑃𝑟𝑆𝑘(z) is converted into a Z-score, where 𝑍𝑘(𝑧) =
𝑃𝑟𝑆𝑘(z)−𝜇𝑘
𝜎𝑘
, where 
𝜇𝑘 and 𝜎𝑘 are, respectively, the mean and standard deviation of all PrS in the kth cluster. A final 
score for ZINC compound, z, is calculated by taking the maximum PrS among all clusters,  
𝑆(𝑧) = max
𝑘
{𝑍𝑘(𝑧)}                                 (5) 
Here, we note that there are overall 3 free parameters in the MAGELLAN pipeline, including 
number of GPCRs used from the alignments, TC cutoff for clustering, and number of clusters used. 
These parameters have been optimized using an independent dataset of 56 GPCRs that are non-
redundant from the test proteins reported in this study. During the training process, the parameters 
were determined by maximizing the average enrichment factor of virtual screening as defined in 
Eq. (7) below. 
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2.4 Construction of Minimum Spanning Tree by Similarity Ensemble Approach 
To evaluate similarity of GPCR proteins based on their ligand similarity, we construct a minimum 
spanning tree for the targets using the similarity ensemble approach (SEA).32-33 To assess the 
ligand set similarities in a statistically stringent base, we first collect multiple random ligand sets 
with sizes between 10 and 1,000 ligands from the GLASS database, and calculate the TC score 
between the randomly collected ligand pairs. The relation of the TC-score distribution and the size 
of ligand sets follows well with 
{
𝜇 = 𝑘𝑠
𝜎 = 𝑚𝑠𝑟
                                 (6) 
where 𝜇 and 𝜎 are mean and standard deviation of the TC-score distribution, 𝑠 is the product of 
the size of two ligand sets compared, and 𝑘,𝑚 and 𝑟 are parameters to fit (see Figure 4.5). Thus, 
Figure 4.4 - Illustration of the ligand profile that summarizes feature information of all ligands from 
the kth cluster. In the ligand profile, the horizontal axes represent the ligand fingerprint bits, while the 
vertical axes indicate the ligands; each ligand contains a corresponding weight (wi) based on GPCR 
alignment scores. The bottom shows a compound fingerprint from ZINC database which is scored. For 
each ligand in the ligand profile, a Tanimoto coefficient (Ti,z) is calculated against the ZINC compound 
and multiplied with its corresponding weight. The average of these values among the ligand profile is 
the 𝑃𝑟𝑆𝑘(z). 
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the fitting parameters are used to convert any raw TC-score of two ligand sets to a size-independent 
Z-score by 𝑍 = (𝑇𝐶 − 𝜇)/𝜎. 
Here, only the ligand pairs with TC score above a threshold are used in the statistical calculation, 
where a TC threshold of 0.84 is found to be optimal, which has the Z-score distribution follow the 
Gumbel distribution (Figure 4.6). Using the extreme value distribution data, a BLAST-like E-value 
can be calculated for each GPCR pairs. Finally, a minimum spanning tree based on the significance 
of E-value can be calculated using Kruskal’s algorithm,34 with the image generated with 
Cytoscape.35  
 
 
Figure 4.5 - Mean and standard deviation of ligand similarities between random ligand sets from the 
GLASS database versus the product of set sizes. Only the ligand pairs with a Tanimoto coefficient above 
0.84 are calculated and the data follow well the linear and power-law equation shown in Eq. (6). 
Figure 4.6 - Z-score distribution of the random background data from GLASS database. The Tanimoto 
coefficient of 0.84 was found to be the best fit with the Gumbel distribution. 
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2.5 On-line Webserver Construction 
An online web server of MAGELLAN is constructed at 
https://zhanglab.ccmb.med.umich.edu/MAGELLAN/, using Python CGI scripting, complemented 
with MySQL, Javascript, and PHP. The MAGELLAN algorithm implemented on the web server 
is the same as that described in the present study, with the exception that it uses TM-HMM to 
determine the transmembrane domains of the unknown query GPCR.36 The user is able to supply 
optional inputs, such as annotated transmembrane domains, a GPCR structure, or the binding site 
residues, in order to bypass GPCR-I-TASSER and COACH that can reduce the job runtime. All 
ligand and test sets filtered from GLASS database are provided for download for the user. 
Additionally, the top 1% of results from screening the full ZINC database for all human GPCRs 
are pre-generated and made available publicly.  
 
3. Results 
3.1 Comparison of MAGELLAN with Component Methods 
Five different alignment methods have been used in MAGELLAN for GPCR model collection. To 
justify the profile approach, we first examine the performance of MAGELLAN in comparison with 
the individual alignment methods, in which the same procedure is implemented as shown in Figure 
4.2, but only with the GPCR models detected by an individual method.  
 
3.1.1 Testing Dataset Construction and Performance Evaluation 
The test datasets are constructed from a comprehensive list of all 224 Class A GPCRs. For each 
GPCR, the active ligands are collected from GLASS database,17 which are filtered with a stringent 
activity threshold of 1 µM for Ki, Kd, IC50, and EC50 values. In order to increase chemical diversity 
and to even out set sizes, ligands were clustered for each GPCR by their Bemis-Murcko 
frameworks.37 If there were between 100 and 600 frameworks, the highest activity ligand was 
selected from each cluster. If there were fewer than 100 frameworks, the highest activity ligands 
were chosen regardless of their framework until a total of 100 ligands was achieved. If there were 
greater than 600 frameworks, the activity threshold was decreased by a factor of 2 until there were 
fewer than 600 frameworks, wherein the highest activity ligands were selected from each 
framework. As a result, the test set consists of 224 Class A GPCRs, which are associated with in 
total 54,438 active ligands, or on average 258 per GPCRs. 
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To test the methods, the active ligands from each GPCR are mixed with a set of 500,000 randomly-
selected compounds as decoys from the “Clean Drug-Like” subset of the ZINC database. The 
downloaded compounds were in SMILES string format and subsequently converted into Morgan 
fingerprints with RDKit,28 consisting of 1,024-bit fingerprints with a radius of 2. A retrospective 
virtual screen (RVS) experiment is implemented by different methods, where the goal of RVS is 
to prioritize the active ligands using the proposed scoring functions. The performance of RVS can 
be qualitatively measured by the enrichment factor (EF): 
𝐸𝐹𝑥% =
𝑁𝑎𝑐𝑡
x%
𝑁𝑠𝑒𝑙𝑒𝑐𝑡
𝑥% 
𝑁𝑎𝑐𝑡
𝑁𝑡𝑜𝑡
 
                                 (7) 
where 𝑁𝑎𝑐𝑡 and 𝑁𝑡𝑜𝑡 are the total numbers of the active and all compounds in the ligand pool, 
respectively. 𝑁𝑎𝑐𝑡
𝑥%  and 𝑁𝑠𝑒𝑙𝑒𝑐𝑡
𝑥%  are, respectively, the numbers of true positive ligands and the 
number of all candidates in the top 𝑥% of the compounds selected by the RVS methods. A higher 
𝐸𝐹𝑥  indicates a better RVS performance, where 𝐸𝐹𝑥 = 1  means a random selection without 
enrichment. While 𝑥% can be taken as different cutoff (1%, 2%, 5% etc), we focus mainly on 1% 
for the briefness of data presentation. 
 
To rule out the effect from using close homologous targets, a handicap was applied to the selection 
of GPCRs, where any homologous GPCR templates with greater than 30% sequence identity to 
the query, based on the BLAST alignment, were excluded. Without this handicap, only the query 
GPCR is excluded. Meanwhile, to challenge the pipeline, a homologous cutoff has been applied 
in the GPCR-I-TASSER structure modeling and COACH binding prediction, i.e., all structures 
with a sequence identity >30% to the query GPCR sequence are excluded from the threading 
template library no matter if the handicap of binding GPCR is applied. 
 
3.1.2 MAGELLAN Significantly Outperforms Component Pipelines in RVS Experiment 
In Figure 4.7A, we present a scatter plot of the enrichment factors (𝐸𝐹1% ) acquired from 
MAGELLAN, in comparison with that from the five individual pipelines, where a cutoff of 30% 
sequence identity was used for filtering out the close homologous GPCR templates when inferring 
the ligand profiles. It was shown that MAGELLAN achieves a higher enrichment factor than the 
individual pipelines for most of the GPCRs. For example, MAGELLAN outperforms the BindRes 
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pipeline in 130 cases, while BindRes does so in 72 cases. These numbers are 146/52, 115/77, 
121/67, and 129/70 for BLAST, PSI-BLAST, PPS-align, and TM-align pipelines respectively. 
 
 
 
In Table 4.1 (Columns 2 and 3), we also list the average and median 𝐸𝐹1% values for each method, 
which again shows that MAGELLAN achieved a higher enrichment factor than all the individual 
methods. To examine the significance of the difference, a Wilcoxon signed-rank test is calculated 
for each pair of the comparison, where the two-tailed p-value is equal to or below 5 𝑥 10−3 in all 
the cases, which indicates that the differences between MAGELLAN and the individual methods 
are statistically significant.  
 
When comparing the individual methods, TM-Align performed better than the other component 
methods, as evidenced by its higher median 𝐸𝐹1% of 13.76. As structure is more conserved than 
sequence, it is of no surprise that it was able to achieve such a result. However, no single method 
by itself contributed dominantly to MAGELLAN because the p-values between MAGELLAN and 
each of them were significant, signifying the synergistic effect of data fusion. 
 
In Figure 4.7B, we also present the results without using the 30% sequence identity cutoff, but the 
target GPCRs have been excluded from the ligand profile detection process. As expected, the RVS 
Table 4.1 - Summary of RVS results by MAGELLAN and component methods. Data shown are median 
and average (in parentheses) 𝐸𝐹1% values on 224 test Class A GPCRs. P-value is calculated in the 
Wilcoxon signed-rank test between MAGELLAN and the control methods. 
Methods 
With handicap Without handicap 
𝐸𝐹1% p-value 𝐸𝐹1% p-value 
MAGELLAN 14.38 (23.03) -- 62.03 (59.13) -- 
BindRes 10.19 (17.90) 5 x 10-7 56.39 (56.35) 4 x 10-6 
BLAST 7.04 (16.49) 5 x 10-14 53.02 (53.26) 1 x 10-14 
PSI-BLAST 11.83 (20.79) 5 x 10-3 54.31 (54.18) 2 x 10-14 
TM-align 13.76 (20.15) 8 x 10-9 56.92 (56.39) 6 x 10-4 
PPS-Align 10.99 (20.25) 2 x 10-6 56.90 (55.55) 1 x 10-6 
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performance becomes much better when homologous GPCRs are included in the ligand profile 
construction, where many of the points in the figure have been shifted to the upper two quadrants 
in the plots, as compared to Figure 4.7A. Interestingly, the synergistic effect as witnessed with the 
handicap is not as pronounced as without the handicap. As shown in Table 4.1 (Columns 4 and 5), 
the average and median 𝐸𝐹1%  values of MAGELLAN are in general higher than that of the 
individual methods. Nonetheless, MAGELLAN overall achieved better performance than the 
individual component methods. 
 
 
Figure 4.7 - Comparison of MAGELLAN and five component methods in the retrospective virtual screen 
experiment on 224 Class A GPCRs. Results are shown as EF1% either with (A) 30% sequence identity 
cutoff or (B) no cutoff. Each point represents one GPCR. The numbers in each triangle represent the 
number of GPCRs for which the RVS method outperforms the comparison ones. 
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3.1.3 Both Sequence and Structural Alignments Are Essential to MAGELLAN Performance 
To further examine the impact of the individual GPCR alignment methods on MAGELLAN’s 
performance, we counted the highest-performing alignment method type for each GPCR under the 
sequence identity handicap, where the type was denoted as either sequence (BLAST, PSI-BLAST, 
BindRes) or structure based (TM-align, PPS-Align). Among the 224 Class A GPCRs, 89 had a 
structure-based method as their top-scoring method with the highest enrichment factors, while the 
sequence-based method does so in 135 cases. Out of the sequence-based methods, 60 of the cases 
were from PSI-BLAST. Overall, the number of GPCRs was relatively evenly distributed for each 
method, and no method stood out in particular, lending credence to the observation that both 
sequence and structural alignments aid in MAGELLAN’s performance with the sequence identity 
handicap. 
 
We also examined the effect of running MAGELLAN without the sequence identity handicap. Of 
the 224 Class A GPCRs examined, 101 resulted in a sequence-based method as their top-scoring 
method, while 123 were from structure-based methods. This was somewhat surprising, as the TM-
Align method produced 94 of the best cases. However, the scoring function from that component 
was likely able to capture homologous GPCR’s better than with sequence alone. Additionally, the 
contributions from BindRes were not menial, having 47 top-scoring GPCRs. Certainly, each 
method played a role in lending their predictive power to MAGELLAN.  
 
3.2 Benchmark of MAGELLAN with Other Virtual Screening Approaches 
To examine MAGELLAN with other state of the art approaches, we tested the performance in 
control with three widely-used virtual screening programs, including AutoDock Vina,6 DOCK 6,7 
and PoLi.5 The former two are receptor-docking based approaches, where the crystal structures of 
the target GPCRs were used as the input for molecular docking. For AutoDock Vina, all 
compounds were converted from Mol2 to PDBQT format. Additionally, the experimental GPCR 
PDB files were converted into the PDBQT format, whereby hydrogens and partial charges were 
added to all PDBQT files. A 30 x 30 x 30 Å3 search space was defined on the receptor so that it 
centered upon the crystal ligand. Default settings were used for the virtual screen, with compounds 
ranked according to their docking scores. For DOCK 6, all GPCR PDB files were converted to the 
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Mol2 format, where hydrogens and partial charges were added. Spheres were selected within 5 Å 
of the crystal ligand, while the scoring grid enclosed the spheres with a 5 Å margin. Flexible 
docking was performed with the recommended settings, with compounds ranked according to their 
grid score. Finally, PoLi is a ligand-based virtual screening tool with the probe ligands detected 
by the binding-pocket structural comparisons between query and templates. As the software is not 
available for installation, the data was taken from the benchmark study of the original authors.5 
The benchmark tests of the methods were performed on two separate datasets from DUD-E38 and 
GPCR-Bench.39 
 
3.2.1 Tests on DUD-E Dataset 
DUD-E38 is a widely-used dataset specially designed for virtual screening benchmarks. It contains 
five Class A GPCR proteins, where each protein has on average 224 active ligands from ChEMBL. 
Each active ligand is paired with 50 molecular decoys (with similar chemistry but of different 
topology) drawn from ZINC. While the turkey beta-1 adrenergic receptor (P07700) was included 
in DUD-E, there is no pharmacological data in any of the ligand databases. Thus, the ligand 
clusters from the human orthologue (P08588) were used in its place. To examine the performance, 
we run MAGELLAN and the three control programs in an automated mode against the ligand 
dataset for each GPCR target, with the goal to pick up the active ligands using their scoring 
functions.  
 
 
 
Table 4.2 - RVS results of EF1% on five Class A GPCRs in DUD-E Dataset. Values out and in parentheses are 
the results for MAGELLAN with or without handicap cutoffs. Data for PoLi was taken from Roy et al.5 
Gene UniProt ID MAGELLAN PoLi AutoDock Dock 6 
AA2AR P29274 0.95 (39.03) 1.2 1.42 2.86 
ADRB1 P07700 5.47 (36.11) 2.0 0.66 2.63 
ADRB2 P07550 13.68 (34.75) 2.6 2.69 1.35 
CXCR4 P61073 0 (23.97) 0 0 2.49 
DRD3 P35462 28.65 (39.27) 5.2 2.64 1.26 
Average  9.75 (34.63) 2.2 1.48 2.12 
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In Table 4.2, we list the 𝐸𝐹1%  value of virtual screening for the five GPCRs, calculated by 
MAGELLAN, AutoDock Vina, and DOCK 6, respectively. Additionally, ROC curves are 
presented in Figure S4, and AUC values are given in Table S1. Here, the PoLi data are directly 
taken from Roy et al,5 in which a similar sequence identity cutoff 30% was applied for the 
homologous GPCR filtering. The data show a better performance of MAGELLAN than the three 
control algorithms for four out of the five tested GPCRs, under the sequence identity cutoff of 
30%. In particular, the dopamine receptor D3 (DRD3) performed exceptionally well with 
MAGELLAN, with an 𝐸𝐹1% 19.06, which is more than 3 times higher than that of the control 
methods (i.e., 5.2, 2.64, and 1.26 by Poli, AutoDock and Dock 6, respectively). With a number of 
related GPCRs selected (P25115 / P21728) from the alignments, the contribution of their ligands 
in the clusters was well established, accounting for 9 chemotypes (Figure 4.8A).  
 
 
The 𝐸𝐹1%  of MAGELLAN is 4.59 and 5.83 for the beta-1 adrenergic receptor and beta-2 
adrenergic receptor, respectively, which is moderately higher than the control methods. The main 
reason for the enhanced performance is due to complementary GPCR pipelines exploited in 
MAGELLAN which detected several closely-related GPCRs that bound with similar ligands 
(including P25100 / P18130 / O02824 for ADRB1, and Q01338 / P23944 for ADRB2), despite 
Figure 4.8 - Proportion of Ligands from Related GPCRs in Clusters from MAGELLAN with Handicap for 
(A) Dopamine Receptor D3 (DRD3) and (B) C-X-C chemokine receptor type 4 (CXCR4). The presence of 
chemotypes containing ligands from respective related GPCRs was examined, where one cluster represents 
one chemotype. The influence of related GPCRs resulted in 9 chemotypes for DRD3, while CXCR4 only 
had one. 
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the low sequence identity. The ligand profiles constructed from the closely-related ligands helped 
prioritize the active compound hits. 
 
However, MAGELLAN yielded a low 𝐸𝐹1%  of 0.95 and 0 for the adenosine A2A receptor 
(AA2AR) and the C-X-C chemokine receptor type 4 (CXCR4), respectively, where no closely-
related GPCRs were selected for the former receptor. Consequently, both receptors could be 
rescued when run without the cutoff, in which related subtypes were correctly detected by both the 
structural and sequence-based GPCR alignment methods. The active ligands thus have 
significantly higher scores than that of the inactive ones for these two cases, which resulted in an 
𝐸𝐹1% of 39.15. The C-X-C chemokine receptor type 4 had a few relatives selected (P51682 / 
P51684 / O54814), but despite their presence, their corresponding ligands were only present in 
one out of the top 40 clusters used in MAGELLAN (Figure 4.8B), suggesting the need for 
chemotype diversity of the set of clusters. Moreover, the ligand set sizes for the related GPCRs 
were very small (56, 65, and 34, respectively), lessening their influence overall.  
 
Altogether, these results highlight the importance of the inclusion of homologous templates for 
ligand profile constructions. This phenomenon was observed for all the receptors, in which 𝐸𝐹1% 
was significantly increased by the inclusion of close homologous GPCRs in ligand profile 
construction. In particular, the number of chemotypes and size of ligand sets from related GPCRs 
appeared to play a role in performance. Overall, the average 𝐸𝐹1% is 9.75, which is 4.4 times 
higher than PoLi, and 6.6 and 4.6 times higher than AutoDock and Dock6 respectively. The 𝐸𝐹1% 
value will increase by 3.6 times if homologous GPCRs are included in the profile construction 
process. 
 
In Figure 4.9, we present the receiver operating characteristic curves (ROC) for the retrospective 
virtual screen results by MAGELLAN and the control methods for all targets, where the 
corresponding area under the curve (AUC) values are listed in Table 4.3. It should be noted that 
we were unable to acquire a ROC curve for PoLi, as we did not have access to their data. Overall, 
MAGELLAN achieved slightly higher AUC values with the handicap cutoffs (AUC=0.69) as 
compared to PoLi (AUC=0.58), AutoDock Vina (AUC=0.64), and DOCK 6 (AUC=0.61). Without 
the handicap cutoff, MAGELLAN was able to attain much better performance (AUC=0.92). This 
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suggests that MAGELLAN is able to better correctly select compounds that would potentially bind 
the GPCR of interest as compared to the benchmarked methods. 
 
 
 
 
 
 
 
Figure 4.9 - ROC Curves for Retrospective Virtual Screen Results of MAGELLAN, AutoDock Vina, and 
DOCK 6 with DUD-E Dataset. The following GPCRs were tested: beta-2 adrenergic receptor (ADRB2), 
beta-1 adrenergic receptor (ADRB1), adenosine receptor A2A (AA2AR), dopamine D3 receptor (DRD3), 
and C-X-C chemokine receptor type 4 (CXCR4). 
Table 4.3 - Comparison of receiver operating characteristic (ROC) values by MAGELLAN, PoLi, AutoDock 
Vina, and Dock 6 on 5 Class A GPCRs in DUD-E. Values out and in parentheses are the results for 
MAGELLAN with or without handicap cutoffs. 
Gene Name UniProt ID MAGELLAN PoLi AutoDock Vina Dock 6 
AA2AR P29274 0.63 (0.96) 0.53 0.62 0.71 
ADRB1 P07700 0.58 (0.92) 0.62 0.63 0.64 
ADRB2 P07550 0.81 (0.96) 0.56 0.67 0.66 
CXCR4 P61073 0.56 (0.85) 0.49 0.59 0.57 
DRD3 P35462 0.85 (0.91) 0.70 0.70 0.48 
Average 0.69 (0.92) 0.58 0.64 0.61 
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3.2.2 Tests on GPCR-Bench Dataset 
The second benchmark dataset on which we conducted experiments is GPCR-Bench;39 it contains 
20 Class A GPCRs, where each GPCR has between 100 to 600 active ligands accompanied by 50 
decoys per active ligand. The RVS results on this benchmark are summarized in Table 4.4. 
 
 
 
In total, MAGELLAN performed favorably (average 𝐸𝐹1%  = 13.70) in this benchmark, as 
compared with AutoDock Vina (average 𝐸𝐹1% =3.16) and DOCK 6 (average 𝐸𝐹1% =3.47). 
AutoDock Vina and DOCK 6 achieved the best enrichment for the free fatty acid receptor 1 
(GPR40) with an 𝐸𝐹1%=24.28 and 21.84 respectively. Since all of its active ligands belong to the 
same chemotype,39 the binding pocket of this target does not have as much variation compared 
with other more challenging targets, and thus makes it easier for docking (Figure 4.10). 
Table 4.4 - Summary of EF_(1%) results on 20 Class A GPCRs in GPCR-Bench. Values out and in parentheses 
are the results for MAGELLAN with or without handicap cutoffs. 
Gene UniProt ID MAGELLAN AutoDock Dock6 
GPR40 O14842 22.04 (48.92) 24.28 21.84 
OX2R O43614 7.92 (34.65) 1.82 0 
ADRB2 P07550 24.64 (60.87) 0.20 9.40 
ADRB1 P07700 1.03 (54.36) 0 2.73 
ACM2 P08172 23.00 (36.00) 7.76 7.12 
ACM3 P08483 24.88 (48.26) 2.31 8.97 
S1PR1 P21453 0.50 (51.24) 0.47 0.16 
PAR1 P25116 0.00 (0.00) 13.39 2.00 
5HT1B P28222 16.83 (60.89) 1.54 2.79 
AA2AR P29274 0.48 (34.13) 0 0.64 
OPRD P32300 27.93 (65.77) 3.77 0.75 
HRH1 P35367 21.39 (50.75) 3.28 0.22 
DRD3 P35462 46.27 (60.70) 1.24 1.03 
OPRK P41145 12.94 (47.76) 0.65 0.22 
OPRX P41146 2.99 (24.38) 0.25 2.85 
5HT2B P41595 18.41 (20.40) 0.98 0.98 
OPRM P42866 2.44 (58.54) 0 1.08 
CCR5 P51681 4.06 (23.86) 0.53 4.36 
CXCR4 P61073 4.26 (70.21) 0 0.26 
P2Y12 Q9H244 11.94 (13.43) 0.76 2.03 
Average 13.70 (43.26) 3.16 3.47 
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MAGELLAN attained a comparable enrichment on this target with 𝐸𝐹1% =22.04; if the 
homologous templates are included, however, the performance is significantly improved to 
𝐸𝐹1% =48.92. Additionally, AutoDock Vina achieved decent enrichment with the protease-
activated receptor 1 (PAR1) at 𝐸𝐹1%=13.39, while MAGELLAN resulted in 𝐸𝐹1%=0.00 with a 
handicap. In fact, MAGELLAN detected several protease-activated receptor subtypes (Q63645, 
P55085, Q96RI0), but their respective ligand sets were of a very small size (2, 59, 10, respectively). 
As a result, their related ligands were not present in the top 40 clusters because of the minority of 
binding ligands, which resulted in the reduced performance. While most of the successful 
examples of GPCRs are found to have at least one related subtype that had a sizeable number of 
ligands, the data suggests that the number of ligands in the ligand sets of closely-related members 
is essential to the success of MAGELLAN, in addition to its ability to detect homologous GPCRs. 
 
 
In Figure 4.11, we also present the log receiver operating characteristic curves (ROC) for the 
retrospective virtual screen results by MAGELLAN and the two control methods for all targets, 
where the corresponding Boltzmann-enhanced receiver operating characteristic (BEDROC, α=20) 
values are listed in Table 4.5. Here, as opposed to the conventional receiver operating characteristic 
(ROC), BEDROC has the advantage to better assess early enrichment,40 which is important as 
Figure 4.10 - Top 5 Active Compound Results for Free Fatty Acid Receptor 1 Using AutoDock Vina. Note 
that the binding pocket resides between two of its transmembrane domains, extending from the lipid bilayer 
to the inner cavity of the receptor. As is evident from the structure of the docked ligands, they share an 
obvious chemotype that also extends to the rest of the active set. 
90 
 
compounds selected for experimental validation are always chosen from top-ranked candidates. 
Overall, MAGELLAN exhibited a higher average early enrichment both with (BEDROC=0.32) 
and without (BEDROC = 0.68) the handicap cutoffs, as compared to AutoDock Vina 
(BEDROC=0.16) and DOCK 6 (BEDROC=0.14). This suggests again that MAGELLAN has a 
higher propensity to correctly select compounds that would potentially bind the GPCR of interest.  
 
Figure 4.11 - Log ROC Curves for Retrospective Virtual Screen Results of MAGELLAN, AutoDock Vina, and DOCK 6 with 
GPCR-Bench Dataset. The following GPCRs were tested: free fatty acid receptor 1 (GPR40), orexin receptor 2 (OXR2), beta-
2 adrenergic receptor (ADRB2), be ta-1 adrenergic receptor (ADRB1), muscarinic acetylcholine receptor 2 (ACM2), 
muscarinic acetylcholine receptor 3 (ACM3), sphingosine 1-phosphate receptor (S1PR1), proteinase-activated receptor 1 
(PAR1), 5-hydroxytryptamine receptor 1B (5HT1B), adenosine receptor A2A (AA2AR), delta opioid receptor (OPRD), 
histamine H1 receptor (HRH1), dopamine D3 receptor (DRD3), kappa opioid receptor (OPRK), nociception receptor (OPRX), 
5-hydroxytryptamine receptor 2B (5HT2B), mu opioid receptor (OPRM), C-C chemokine receptor type 5 (CCR5), C-X-C 
chemokine receptor type 4 (CXCR4), and purinergic receptor (P2Y12). 
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Table 4.5 - Comparison of Boltzmann-enhanced receiver operating characteristic (BEDROC) values by 
MAGELLAN, AutoDock Vina and Dock 6 on 20 Class A GPCRs in GPCR-Bench. Values out and in parentheses 
are the results for MAGELLAN with or without handicap cutoffs. 
Gene Name UniProt ID MAGELLAN AutoDock Vina Dock 6 
GPR40 O14842 0.46 (0.87) 0.59 0.35 
OX2R O43614 0.26 (0.51) 0.12 0.03 
ADRB2 P07550 0.45 (0.94) 0.17 0.23 
ADRB1 P07700 0.07 (0.92) 0.07 0.23 
ACM2 P08172 0.54 (0.62) 0.11 0.21 
ACM3 P08483 0.49 (0.69) 0.07 0.13 
S1PR1 P21453 0.06 (0.80) 0.22 0.13 
PAR1 P25116 0.06 (0.06) 0.34 0.26 
5HT1B P28222 0.42 (0.92) 0.07 0.02 
AA2AR P29274 0.10 (0.58) 0.29 0.13 
OPRD P32300 0.60 (0.84) 0.08 0.19 
HRH1 P35367 0.43 (0.80) 0.11 0.18 
DRD3 P35462 0.69 (0.83) 0.09 0.07 
OPRK P41145 0.33 (0.75) 0.13 0.08 
OPRX P41146 0.15 (0.46) 0.18 0.04 
5HT2B P41595 0.38 (0.44) 0.16 0.06 
OPRM P42866 0.16 (0.82) 0.12 0.12 
CCR5 P51681 0.20 (0.49) 0.04 0.05 
CXCR4 P61073 0.28 (0.81) 0.06 0.09 
P2Y12 Q9H244 0.33 (0.49) 0.09 0.14 
Average 0.32 (0.68) 0.16 0.14 
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3.3 Case Studies: Using MAGELLAN Prediction for Common Drug Targets and De-
orphanization 
3.3.1 Mu Opioid Receptor 
One of the main purposes of MAGELLAN is to predict compounds that could potentially be 
developed into clinically useful drugs. As an illustration towards this goal, we examined here a 
medically-important target, the mu opioid receptor (UniProt ID: P35372), which is closely 
involved in the reduction of pain. Common drugs in pain reduction include morphine and heroin, 
which are both strong opioid agonists. However, a major side effect of their consumption often 
results in various unwanted side effects, such as nausea, constipation, respiration depression, and 
addiction; as a result, many current research efforts have been trying to develop drugs with the 
analgesic effect while trying to reduce or eliminate the aforementioned maladies.41  
 
From the retrospective virtual screen experiment performed without sequence identity cutoff, a 
high 𝐸𝐹1% of 87.81 was achieved for the human mu opioid receptor. This is not surprising, as 
many opioids are notorious for their promiscuous binding to the opioid family of receptors, which 
also comprise additionally of the kappa opioid, delta opioid, and nociceptin receptors. All GPCR 
alignment methods exploited were able to select at least one of these receptors. Using a similarity 
ensemble approach analysis of the GPCR test sets as described in Methods, we have constructed 
a minimum spanning tree based on the similarity of the test sets identified by MAGELLAN, where 
all the opioid receptors were found pharmacologically related (Figure 4.12, blue nodes). 
 
From these results, it is clear that the application of MAGELLAN to known drug targets, such as 
the mu opioid receptor, can yield accurate virtual screening results. More importantly, a fraction 
of top-ranking results could be used sequentially as a targeted library in a structure-based virtual 
screen campaign, such as docking, in order to address the shortcomings of ligand-based virtual 
screening methods.8 As docking can be computationally expensive, MAGELLAN can thus serve 
as a relatively-quick filtration step of the database of interest. 
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3.3.2 Motilin Receptor  
Apart from drug discovery, MAGELLAN can be extended to GPCR de-orphanization. As orphan 
GPCRs have either no identified endogenous ligand or unknown function, they likely have an 
undiscovered physiological role likely to be intertwined with disease and remain potential 
therapeutic targets in drug discovery. For the purposes of this study, we have chosen to examine a 
former orphan GPCR, the human motilin receptor (UniProt ID: O43193), to illustrate the de-
orphanization process of MAGELLAN. 
 
It is known that the closest-related GPCR to the motilin receptor is the growth hormone 
secretagogue receptor type 1 (also known as ghrelin receptor), with a sequence identity of 51% 
between the human variants. With such a high sequence identity, it was predicted that 
MAGELLAN would be able to enrich for reference compounds. With no sequence identity cutoff, 
an 𝐸𝐹1% of 33.33 was achieved. Every alignment method was able to select multiple orthologues 
of growth hormone secretagogue receptor type 1. An example BindRes alignment between the 
human motilin receptor and pig pig growth hormone secretagogue receptor type 1 is given in 
Figure 4.13, where it is apparent that there is high sequence identity (~70%) between the aligned 
Figure 4.12 - Ligand set similarity map constructed from MAGELLAN predictions on the GPCR test sets. 
Each node corresponds to a GPCR ligand set. The map was created using Kruskal’s algorithm based on E-
values of the ligand sets calculated by the similarity ensemble approach (SEA). 
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binding site residues. Once again using SEA analysis, it was shown that the ligand sets of this 
receptor and the motilin receptor were pharmacologically similar (Figure 4.12, red nodes) and 
likely to have contributed to the high enrichment. It should be noted that there were no ligand sets 
corresponding to any orthologues of the motilin receptor; there was ligand set data for only the 
human variant. Taken together, these data suggest the feasibility for the application of 
MAGELLAN in efforts to deorphanize GPCRs.  
 
 
4. Discussion 
Built on the assumption that similar receptors bind with similar ligands, we have developed a new 
hierarchical, ligand-profile based approach, MAGELLAN, to virtual drug screen targeting Class 
A GPCRs. Starting from amino acid sequence of the target proteins, MAGELLAN first utilizes 
GPCR-I-TASSER23 to generate tertiary structure prediction for the target protein. Next, five 
pipelines of structure, sequence and orthosteric binding-site based alignment methods are extended 
to the detection of homologous and analogous proteins, where all known ligands bound with the 
proteins are clustered for the construction of a set of chemical profiles; these are finally used to 
Figure 4.13 - BindRes Alignment for Human Motilin Receptor. BW refers to the Ballesteros-Weinstein 
numbering scheme for the binding site residues, while the query and target are the human motilin receptor 
(UniProt: O43193) and pig growth hormone secretagogue receptor type 1 (UniProt: Q95254), respectively. 
The colons depict residues that are identical. 
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match through the compound libraries for screening putative ligands and drugs for the target 
receptor. 
 
The method was first tested on a comprehensive set of 224 Class A GPCRs and achieved a median 
enrichment factor 𝐸𝐹1%  of 15.31 after excluding all homologous templates in both structure 
prediction and GPCR template detection processes, which is significantly higher than the pipelines 
using individual GPCR alignment methods. In addition, MAGELLAN was tested on two 
independent benchmark sets from DUD-E38 and GPCR-Bench,39 consisting of 5 and 20 Class A 
GPCRs, and compare favorably with other state-of-the-art docking and ligand-based virtual 
screening approaches, including AutoDock Vina,6 DOCK 6,7 and PoLi.5 Detailed data analysis 
shows that the major advantage of MAGELLAN lies at the utilization of both structure (including 
global and local) and orthosteric binding-site based comparisons for GPCR template detections, 
whereas the ligand profiles constructed from the multiple resources of data fusion help enhance 
the sensitivity and specificity of the virtual screening through the compound databases. 
 
Apart from the favorable benchmark performance, several advances may help future MAGELLAN 
developments. First, MAGELLAN is a ligand-profile based approach utilizing only ligand-GPCR 
associations. This is different from other ligand-oriented approaches, such as PoLi which relies on 
known ligand-protein complex structures from the BioLip.42 Currently, the number of non-
redundant ligand-GPCR associations from GLASS with experimental data is 533,470, which is 
over 7,500 times higher than the number of known, non-redundant ligand-GPCR complexes in 
BioLiP; this is part of the reason for the significant improvement of MAGELLAN over PoLi. The 
gap between the ligand-receptor association and the protein binding structure databases are rapidly 
increasing15-17, 43, which should give additional advantage and potential to the future development 
of the ligand-based methods such as MAGELLAN.  
 
Compared to the docking-based approaches, MAGELLAN has the advantage in utilizing low-
resolution predicted structures, since high-resolution experimental structures are often unavailable 
to many important drug targets. Technically, it is also a benefit to exploit the global fold 
comparison for GPCR template detection because many experimentally--solved structures are in 
unbound apo form, which can significantly impact the accuracy of the docking-based approaches 
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that often have difficulty in modeling the ligand-induced conformational changes. In addition, 
docking a large library of compounds is very computationally expensive and time consuming. As 
experienced in this study, it typically took days to weeks for AutoDock Vina or DOCK 6 to 
complete a docking screen for a single GPCR, depending on the target; conversely, ligand-based 
virtual screening using MAGELLAN only takes about an hour. Nevertheless, docking based 
programs have the advantage to generate 3D model of binding structures that is often useful for 
additional function and drug-based analyses. Meanwhile, we also found that there are several cases 
(such as GPR40 and PAR1) for which the docking-based approach achieve a much higher 
enrichment. Thus, a combination of MAGELLAN with structure-based docking should further 
improve the functionality and accuracy, which is currently under development. 
 
It is important to note that one feature of MAGELLAN is its potential in discovering new ligands 
for orphan GPCRs. Since it is not limited by the PDB and utilizes related GPCRs to infer potential 
ligands, compounds ranked from a screening database by MAGELLAN could be selected and 
experimentally validated with biological assays. Currently, there are 87 Class A, 8 Class C, and 
26 adhesion orphan GPCRs, according to a recent overview,44 meaning that there is much more to 
discover. As illustrated in Figure 7, the motilin receptor, a former orphan Class A GPCR, achieved 
a moderately-high enrichment in a retrospective virtual screen. While this and other examples can 
only be validated with experimental, pharmacological studies in prospective screens, the data 
demonstrated an additional aspect of applications of MAGELLAN to the deorphanization of 
GPCRs. 
 
5. Conclusion 
Overall, we believe that MAGELLAN has surpassed the status quo, given the benchmark results 
against other state-of-the-art virtual screening algorithms. Based on the aforementioned case 
studies, our algorithm is readily applicable to the numerous orphan GPCR’s whose functions and 
endogenous ligands remain to be elucidated. Moreover, it can also be used as a ligand-based virtual 
screening method and would likely prove useful in prospective virtual screening studies where 
information about the receptor is scant. Lastly, a user-friendly web server is provided for 
researchers interested in virtually screening a GPCR of interest against ZINC database. 
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CHAPTER 5.  
Development of a Combined Ligand-  and Structure-Based Virtual Screening Approach 
for the Discovery of Novel Bifunctional μ-Opioid Agonist/δ-Opioid Antagonist Compounds 
 
1. Introduction  
Opioids are a class of molecules commonly used in drugs for regulating pain. Despite their 
effectiveness as pain killers, available opioids commonly result in deleterious side effects, such as 
constipation and respiratory depression.1 Compounded with their addictive nature, the North 
American continent has been experiencing an ever-worsening opioid epidemic, resulting in 
increasing numbers of deaths from drug overdose in recent years. However, opioids still remain 
commonly prescribed for pain relief.  
 
Long-term opioid usage has become more prevalent, but data establishing the efficacy of its long-
term efficacy is scant.2 Additionally, many physicians have begun to refer patients to specialists, 
which are typically neurologists; given the small specialist-to-patient ratio, this could potentially 
delay the management of pain.2 With the long-term use of opioids comes the increased risk of 
addiction and misuse. In 2015 alone, there were reported to be about 2.4 million Americans 
classified as having abused opioids.3 Compounding this is the ever-increasing amount of deaths 
resulting from opioid-related overdoses, increasing from 28,647 in 2014 to 33,091 in 2015.4 With 
the opioid epidemic declared a public health emergency by the president of the United States of 
America in late 2017, it is imperative that safer, more efficacious opioids be developed to address 
the current status in pain management. 
 
The opioid receptors are a family of G protein-coupled receptors (GPCR) responsible for the 
modulation of pain, motor control, and mood. Three subtypes (μ, δ, and κ) are pharmacologically 
mediated by opioids. The μ-opioid receptor (MOR) is the classical target associated with the 
analgesic effect of opioids. Apart from this intended effect, a plethora of side effects, such as 
respiratory depression, nausea, sedation, addiction, and constipation, accompany the use of 
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opioids.1 As a result, the δ-opioid receptor (DOR)5 and κ-opioid receptor (KOR)6 have increasingly 
been seen as potential targets in drug development for novel opioids with reduced side effects.  
 
Historically, there have been numerous efforts to develop an opioid that could exert analgesia 
while reducing or eliminating all associated side effects. In the late 19th century, Bayer marketed 
heroin as a non-addictive alternative to morphine in an effort to combat opioid addiction, though 
years afterwards it was revealed that users were ironically becoming addicts.7 More recent research 
has tended to focus on the phenomenon of biased agonism, whereby a ligand could stabilize the 
conformation of a GPCR so that it preferentially goes through one signal transduction pathway by 
recruiting a heterotrimeric G protein over β-arrestin or vice versa.8 Taking advantage of this, there 
have been several success stories with various GPCRs, especially in the development of opioids 
with reduced side effects; one of the most promising compounds found currently is oliceridine 
(TRV130) from Trevena,9 which is awaiting NDA review at the time of writing. As with 
oliceridine, the vast majority of drug discovery efforts employ high throughput screening in order 
to sift through a gargantuan sea of chemical diversity to find functional compounds. However, this 
process is usually costly, time consuming, and laborious, so thus in silico methods, such as 
molecular docking, can be utilized to reduce the chemical space by screening a virtual compound 
library and selecting only prioritized compounds for pharmacological assays.10  
 
Figure 5.1 – (A.) Compounds that act as a MOR agonist and DOR antagonist can both elicit analgesia and reduce tolerance 
and dependence in animal models. The black and red lines represent agonist and antagonist function, respectively. (B.) 
Compound 14a is a bifunctional peptidomimetic opioid with a tetrahydroquinoline (THQ) scaffold, which is shown in red. 
A. B. 
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There have been a number of computational studies reporting their findings on discovering biased 
agonists for MOR11 and KOR12-13 through in silico methods. While probing the concept of biased 
agonism remains a fertile area of research, an alternate mode to eliciting analgesia with reduced 
side effects has been steadily coming into the spotlight, as well. More specifically, studies have 
shown that co-administration of a MOR agonist and a DOR antagonist produces such a response 
in animal models.14 Moreover, mixed-efficacy (a.k.a. bifunctional) MOR agonist/DOR antagonist 
compounds have been developed by several groups at the University of Michigan and shown to 
bind to both MOR and DOR while only activating MOR (Figure 5.1A).15-16 In particular, the 
synthetic peptidomimetic opioid, compound 14a (Figure 5.1B), was shown to have a very 
promising safety profile.16 Additionally, other groups have concurrently developed bifunctional 
ligands with different scaffolds and similar effects.17-18 Despite the potential of these bifunctional 
opioids as therapeutics, the compounds from these studies were based on traditional opioid 
structures, and thus, novel scaffolds that can potentially be developed into more efficacious, safer 
analgesics remain to be discovered. Importantly, one gap that has yet to be filled in this area of 
research is the application of in silico methods to the discovery of such compounds. 
 
Most virtual screening campaigns performed today, such as the aforementioned virtual screening 
campaigns with biased agonists, tend to focus on a single target and a single screening method, 
but these can provide challenges for the discovery of bifunctional opioids. First, screening methods 
can typically be categorized as ligand based or structure based; the former utilizes pure chemical 
information in its search process, whereas the latter docks and scores compounds into a receptor 
structure. As with any method, there are advantages and disadvantages to each. Ligand-based 
methods are computationally inexpensive and can screen millions of compounds within a short 
time but have the drawback of being biased towards the known ligands used to build the model. 
Conversely, structure-based methods inherently have no bias, but they are extremely 
computationally expensive. A trend in recent years has culminated in the combination of these 
methods to address their respective shortcomings in various studies19 and thus would be 
meaningful to pursue. Second, instead of screening one target, both MOR and DOR would have 
to be screened. A study employing a dual-target virtual screening approach against the serotonin 
1B and 2B as target and anti-target, respectively, found selective agonists, which lends credence 
to this concept.20  
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In the present study, I present a combined ligand-based and structure-based virtual screening 
pipeline for the discovery of novel bifunctional opioids. The druglike subset of ZINC database21 
was screened against MOR and DOR sequentially using MAGELLAN, followed by docking with 
AutoDock Vina.22 Docking results were then post-processed on the basis of rescoring, chemical 
novelty, and co-existence in top-ranked compounds of both MOR and DOR. Compounds selected 
for experimental validation were chosen from a combination of clustering and visual inspection. 
 
2. Methods  
All of the following procedures were performed with custom scripts in Perl and Python under the 
Red Hat Linux operating system. Retrospective virtual screens were run on a local computing 
cluster, while the prospective virtual screens were submitted to the Comet computing resource 
from XSEDE.23 The chemical novelty filter was written in the C programming language. 
 
2.1 Virtual Libraries  
The druglike subset of ZINC12 database21 served as the virtual library, consisting of over 13 
million compounds prefiltered by Lipinski’s rule of five.24 For the ligand-based portion of the 
virtual screen, the database was downloaded as SMILES strings and converted into 1,024-bit 
Morgan fingerprints with a radius of 2 using RDkit.25  For the structure-based portion of the virtual 
screen, the corresponding compounds in MOL2 format were downloaded and converted into 
PDBQT files using relevant Python scripts from AutoDockTools,26  in which hydrogens and partial 
charges were re-added.  
 
Active and decoy sets for MOR and DOR from GPCR-Bench27 were downloaded from the DUD-
E database28 in the MOL2 and SMILES formats. For every active compound, there were 50 decoys 
with similar physicochemical properties but dissimilar 2D topology. Like before, all compounds 
were converted to PDBQT format, with re-added hydrogens and partial charges. Furthermore, all 
SMILES strings were converted into 1,024-bit Morgan fingerprints with a radius of 2 using 
RDkit.25   
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2.2 GPCR Structure Preparation 
The agonist-bound MOR (PDB: 5C1M) and antagonist-bound DOR (PDB: 4EJ4) structures were 
downloaded from Protein Databank in PDB format. These were structures were selected because 
of their activation states, as the goal of the study is to predict bifunctional MOR agonist / DOR 
antagonist compounds. All small molecules and ions were removed from the PDB structures. In 
the original MOR structure, His54 on the N-terminus forms an interaction with the secondary 
amine of the agonist, BU72, though it was found not to be physiologically relevant by 
experiment.29 Therefore, the N-terminus was removed to prevent the occlusion of the rest of the 
binding pocket. Conversely, the DOR structure did not require such a modification. Similar to the 
virtual libraries, the receptor structures were converted to PDBQT format, where hydrogens and 
partial charges were added with relevant Python scripts from AutoDockTools.26 For AutoDock 
Vina,22 16 Å x 16 Å x 16 Å boxes were centered over the binding pockets for each receptor 
according to their crystallographic ligands. 
 
2.3 Retrospective Virtual Screen 
MAGELLAN and AutoDock Vina, respectively, were the ligand- and structure-based algorithms 
used in present virtual screen campaign. In the former algorithm, known ligands from sequentially- 
and structurally-related GPCRs are used to infer what ligands a target GPCR would bind using a 
consensus chemical similarity approach, while in the latter, a compound is docked into the binding 
pocket of a receptor, conformationally sampled for the most optimal pose, and assigned a score. 
Retrospective virtual screening is typically employed to validate the performance of the virtual 
screening method and to gauge how likely it would succeed in the wet lab. To do so, a virtual 
library is spiked with known active ligands, and the algorithm of interest would aim to acquire as 
many active ligands as possible within a set number of top-ranked compounds. Enrichment factors 
are then calculated to provide a quantitative metric of how many fold over random the algorithm 
is operating. The calculation for the enrichment factor for the top 1% of the top-ranked compounds 
is shown as follows:  
 
𝐸𝐹1% =
𝑁𝑎𝑐𝑡
1%
𝑁𝑠𝑒𝑙𝑒𝑐𝑡
1% 
𝑁𝑎𝑐𝑡
𝑁𝑡𝑜𝑡
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where 𝑁𝑎𝑐𝑡 and 𝑁𝑡𝑜𝑡 are the total numbers of the active and all compounds, respectively. 𝑁𝑎𝑐𝑡
1% 
and 𝑁𝑠𝑒𝑙𝑒𝑐𝑡
1%  are, respectively, the numbers of active ligands and the number of all candidates in 
the top 1% of the ranked database.  
 
Receiver operating characteristic (ROC) curves were generated to evaluate how well it was able 
to discriminate between active and decoy compounds. The false positive rate (FPR) and true 
positive rate (TPR) are defined as the percent actives and decoys found, respectively. The scored 
compounds are ranked, then the FPR and TPR are calculated for each compound starting from the 
top-ranked compound and ending at the last one. Additionally, semi-log ROC curves were 
produced to emphasize the results from the top-ranked compounds of the database. This region of 
the database is the pool from which compounds typically get selected for experimental validation. 
An accompanying metric, Boltzmann-enhanced discrimination of the receiver operating 
characteristic (BEDROC), was used that correspondingly measures enrichment at this region.30 An 
α=20 was used in the calculation, where the top 8% of the database accounted for 80% of the 
BEDROC score.31  
 
 
 
Figure 5.2 – Prospective virtual screening pipeline with post-processing. (Left Panel) The main virtual screening portion 
lies within the inverted triangle. Roman numerals indicate the variations in post-processing procedures used. (Right Panel) 
The letters represent the four different post-processing strategies employed, including the number of compounds selected 
for experimental validation. 
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2.4 Prospective Virtual Screen Pipeline 
An illustration of the prospective virtual screen pipeline is shown in the left panel of Figure 5.2. 
First, ~13 million compounds from ZINC12 database were first screened against both MOR and 
DOR with MAGELLAN. The top 1 million resulting ranked compounds from each receptor were 
pooled together into a targeted library, which consisted of ~1.3 million compounds. AutoDock 
Vina was then run against both MOR and DOR using the targeted library, which was carried out 
using 8 CPU cores and an exhaustiveness of 12. Subsequently, 9 docked poses were generated for 
each compound. 
 
Following docking, the compounds underwent various stages of post-processing in order to 
improve the predictive accuracy and to provide a knowledge-based means to select compounds for 
experimental validation. First, the docked poses were rescored with an independent scoring 
function. Using the docking score from a docking program is typically not advised, as it was very 
likely optimized to find the best docking poses but not the best predicted affinities.32 Therefore, 
many studies have increasingly relied upon rescoring or prioritizing docking poses through a 
separate means.33-35 Both the top-scoring compound (top) or all 9 docked poses (top9) were 
rescored with either the knowledge-based scoring function, DSX,36 or the empirical scoring 
function, X-Score.37 In the case of top9, the poses were reranked on the basis of rescoring, and the 
top-scoring compound and its corresponding score was selected. It should be mentioned that X-
Score was chosen over DSX on the basis of retrospective virtual screening performance and will 
be discussed later.  
 
For both rescoring strategies, compounds were then selected for clustering or visual inspection 
(Figure 5.2, right panel). Compounds colocalizing in the top 5,000 ranked compounds for both 
MOR and DOR were selected and used in a chemical novelty filter. Here, each compound was 
compared against a master list of 5,153 MOR- and DOR-associated compounds with at most 10 
μM in Ki, Kd, EC50, or IC50 from GLASS database.38 If a compound was at least 30% similar by 
Tanimoto coefficient to any ligand in the list, then it was discarded. The compounds were then 
subjected to hierarchical substructure clustering using LibMCS, JChemSuite 18.18.0, 2018, 
ChemAxon (http://www.chemaxon.com). The compounds from the lowest-level clusters were 
rescored by taking the average score from MOR and DOR, and the top-scoring from that cluster 
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was chosen for experimental validation. If there were 10 or more compounds in the cluster, then 
the top one-tenth of the compounds were chosen. Additionally, compounds colocalizing in the top 
20,000 ranked compounds for both MOR and DOR were selected as with the top 5,000 and filtered 
for chemical novelty. PLIP39 was utilized to filter out compounds that had interactions with 
Asp147 of MOR and Asp128 of DOR.11 This was then followed by visual inspection of the 
resulting docked poses using PyMol.  
 
3. Results and Discussion 
3.1 Comparison Between Docked and Experimental Ligand Poses 
As one of the first controls used in docking, reproduction of the experimental pose can provide a 
good initial quality control assessment of the procedure. To do so, the crystallographic ligands 
were stripped from the MOR and DOR structures. Subsequently, they were redocked with 
AutoDock Vina, and the top pose was evaluated. It was shown that pose reproduction with both 
structures produced good overlap between the crystallographic and docked poses, resulting in 
RMSD values with less than 1 Å deviation (Figure 5.3). Typically, RMSD values less than 2 Å 
indicate success in pose reproduction.40 Taken together, this suggests that the docking procedure 
with AutoDock Vina performed adequately with the native ligand.  
 
 
3.2 Model Validation of Ligand- and Structure-Based Methods 
In order to examine and evaluate the ligand-based virtual screening component of the pipeline, 
retrospective virtual screens were run against MOR and DOR using MAGELLAN on the GPCR-
Figure 5.3 – Pose Reproduction of Co-Crystallized Ligands. For both (A) BU72 from MOR and (B) naltrindole from DOR, 
the crystallographic ligands (cyan) are overlain with the top predicted pose (magenta) by AutoDock Vina. Calculated 
RMSDs were 0.7 Å and 0.6 Å, respectively. 
A. B. 
Asp147 
Asp128 
Tyr129 
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Bench dataset. A summary of screening statistics is given in Table 5.1. Overall, both MOR and 
DOR were able to achieve EF1% values greater than 50-fold over random. Its ability to discriminate 
actives over decoys was very favorable (Figure 5.4A). More importantly, high BEDROC values 
(MOR: 0.824 / DOR: 0.842) were indicative of early enrichment in the area of the database where 
researchers would select compounds for experimental validation. Altogether, this suggests that 
MAGELLAN is able to achieve a high level of performance with both MOR and DOR in the 
GPCR-Bench dataset, and thus validate this component in the prospective virtual screening 
pipeline. 
 
 
Figure 5.4 – Performance of MAGELLAN against GPCR-Bench Dataset. (A.) ROC curves are given for both 
MOR and DOR. (B.) Additionally, semi-log ROC curves are shown to emphasize the impact on early enrichment 
in virtual screening. The dashed lines represent random. 
Table 5.1 – Retrospective Virtual Screening Statistics for MAGELLAN 
 EF1% AUC BEDROC (α=20) 
MOR 58.537 0.975 0.824 
DOR 65.766 0.956 0.842 
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Molecular docking with AutoDock Vina was utilized as the structure-based virtual screening 
component of the pipeline. As with MAGELLAN, a retrospective virtual screen was run against 
both MOR and DOR using the GPCR-Bench dataset. A summary of screening statistics is given 
in Table 5.2. Using only the AutoDock Vina scores, enrichment of active compounds was poor for 
both MOR (EF1%=0.000) and DOR (EF1%=3.953). Furthermore, the ability to discriminate active 
compounds over decoys was close to random (Figure 5.5A). To account for this, two strategies 
were employed: 1.) Rescore the top pose from AutoDock Vina (Top), and 2.) Rescore all poses, 
re-rank, then select top pose again (Top9). The scoring function from docking algorithms is 
typically optimized for finding the best pose and is usually not a good substitute for approximation 
of the binding affinities. Additionally, the best pose is not always going to be the pose with the 
highest docking score, as it may be randomly-distributed among all the generated poses when 
ranked by the original docking score.41 It has also been shown that rescoring docked poses with a 
more reliable predictor can result in better correlation between the predicted and experimental 
binding affinities.42 Therefore, DSX and X-Score were utilized for rescoring.  
 
DSX was able to slightly improve enrichment for MOR and DOR using both the Top and Top9 
strategies. Discrimination between active compounds and decoys was also better (Figure 5.5A). 
More striking, however, was the increase in early enrichment (Figure 5.5B); performance with 
DOR saw a slight increase, while that with MOR increased from a BEDROC value of 0.078 to 
0.221 (Top) and 0.201 (Top9). On the other hand, X-Score was able to improve the docking model 
even further than DSX. Enrichment was noticeably increased with this scoring method, where the 
Top9 strategy achieved EF1% of over 10 for both receptors. Discrimination between active 
compounds and decoys was approximately the same for MOR between DSX and X-Score, though 
it improved to a greater extent for DOR (Figure 5.5A). Though early enrichment for MOR 
improved for X-Score as compared to DSX overall, it was extremely noticeable for DOR (Figure 
5.5B). As a result, X-Score was chosen as the rescoring method for the prospective virtual 
screening pipeline.  
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Upon further investigation of the docking scores generated from AutoDock Vina, it was observed 
that few active compounds achieved high ranks for both MOR and DOR (Figure 5.6A). However, 
upon rescoring with X-Score using either the Top (Figure 5.6B) or Top9 (Figure 5.6C) strategies, 
it was apparent that numerous active compounds were able to achieve higher docking scores 
Table 5.2 – Retrospective Virtual Screening Statistics for AutoDock Vina 
 MOR DOR 
 EF1% AUC BEDROC (α=20) EF1% AUC BEDROC (α=20) 
AutoDock Vina 0.000 0.637 0.078 3.953 0.611 0.139 
DSX (Top) 3.239 0.742 0.221 3.765 0.707 0.202 
DSX (Top9) 2.699 0.738 0.201 3.577 0.735 0.228 
X-Score (Top) 7.826 0.750 0.284 8.660 0.812 0.380 
X-Score (Top9) 10.253 0.750 0.283 10.166 0.847 0.424 
 
Figure 5.5 – Performance of Rescoring Docking Poses with GPCR-Bench Dataset. (A.) ROC curves are given for both 
MOR and DOR. (B.) Additionally, semi-log ROC curves are shown to emphasize the impact on early enrichment in 
virtual screening.  
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overall and relative to decoys. As such, this accounts for the increases seen in enrichment factors 
and AUC values for both receptors (Table 5.2). An interesting observation made from the data was 
that there was a slight dependence of the docking scores on the molecular weight of the compounds. 
This has historically been a common problem with scoring functions because larger molecules will 
likely possess higher scores due to their ability to establish a greater amount of interactions with 
the receptor.43 Unfortunately, this means that the prospective virtual screen will likely have a slight 
bias towards higher-molecular weight compounds. Despite this, these larger compounds are 
equally viable as candidates for experimental validation and were treated as such in the current 
study.  
 
 
Figure 5.6 – Improvement of Docking Results with Rescoring Docked Poses. Docking scores from (A.) AutoDock Vina, 
(B.) X-score using the Top strategy, and (C.) X-score using the Top9 strategy are plotted against the molecular weights 
of the respective active compounds (orange) and decoys (blue). A shift of active compounds against decoys was apparent 
after rescoring, though a slight dependence of docking score on molecular weight was observed. 
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An important observation of the validation procedure is that docking appeared to perform worse 
quantitatively than MAGELLAN in the retrospective virtual screening tests against GPCR-Bench. 
While this is true, it must be reiterated that ligand- (i.e. MAGELLAN) and structure-based 
(AutoDock Vina) methods each have their own sets of advantages and disadvantages. While 
ligand-based methods are fast, they typically contain inherent biases towards known active ligands 
built into its algorithm. In contrast, structure-based methods contain no such biases towards any 
existing ligands whatsoever, though they are extremely computationally intensive. The prospective 
virtual screening pipeline was built in such a fashion that MAGELLAN could speedily reduce the 
chemical space of the virtual library, so that it could provide a targeted library for the more 
computationally-demanding AutoDock Vina. Moreover, docking can produce revelations about 
the conformation of a compound in the binding pocket that chemical similarity cannot. For 
example, a similar compound found by ligand-based virtual screening that has additional chemical 
moieties to known active compounds may not work experimentally, whereupon docking could 
account for this with a structure-based prediction on why it does not fit optimally into the binding 
pocket.  
 
3.3 Evaluation of Prospective Virtual Screen 
As a ligand-based method was used as the first step in the prospective virtual screening pipeline, 
there will be an inherent bias in acquiring compounds chemically-similar to the input in the top-
ranking compounds. However, MAGELLAN does not operate solely with known active ligands 
of just MOR or DOR as inputs, as done with similarity-based virtual screening approaches; rather, 
ligands from homologous GPCRs are also used, potentially extending chemical coverage to opioid 
receptor relatives. Under the notion that similar receptors bind similar ligands,44 it is possible that 
novel opioid chemotypes can be inferred from related GPCRs and found in the top-ranked region 
of the virtual library. This was observed from the virtual screening results, where numerous 
compounds passed a chemical novelty filter in which any compound at least 30% chemically 
similar to any known MOR or DOR ligands were excluded from the study. In fact, at least 35% of 
compounds subjected to the novelty filter passed for each of the post-processing strategies 
employed. Taken together, this suggests that MAGELLAN is able to discover novel chemotypes 
and does not entirely adhere to the classical notion of bias towards known active ligands. 
 
113 
 
Through the post-processing strategies involving manual inspection of the docking poses, 81 and 
67 compounds were chosen through Top and Top9, respectively (Table 5.1). An example of 
selection based on interaction with Asp128 for MOR and Asp147 for DOR is given in Figure 5.7. 
It should be noted that the top 20,000 compounds for both receptors were considered, which is 
beyond the coverage of EF1% metric that accounts for the top ~13,000 top-ranked compounds. 
However, it has been previously described that there is merit in looking further down a list of 
ranked compounds, when using visual inspection as a subjective criterion.27 Using this notion, 
compounds were selected in this fashion to increase the chance of selecting active compounds 
based on classical interactions with the receptor. Additionally, clustering of the top 5,000 
compounds for each receptor was performed and compounds selected from each cluster in order 
to generate a chemically-diverse set of compounds without having to require an inordinate amount 
of funding to experimentally validate. An example for this is shown in Figure 5.8, where 
ZINC02131167 was selected on the basis of its average docking score between MOR and DOR. 
Overall, unique 360 compounds were chosen from four different post-processing strategies (Table 
5.1). Note that many compounds overlapped between the strategies, which explains why the 
numbers add up to greater than 360 in the table.  
 
 
 
 
 
 
 
 
 
 
 
 
 
A final control for the prospective virtual screen was the inclusion of compound 14a (Figure 5.1B) 
in the molecular docking validation. For both Top and Top9 strategies, it was able to achieve ranks 
Figure 5.7 – ZINC Compound Selected by Visual Inspection of Docked Poses. (A.) Two secondary amines from 
ZINC09463337 (olive green) were found to form polar interactions with the one of the oxygens of Asp147 (dashed 
yellow lines) from MOR. (B.) A single secondary amine from ZINC09463337 (magenta) was observed to interact with 
the backbone amine of Asp128 (dashed yellow line) from DOR.  
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of 68 (0.005%) and 31 (0.002%) for MOR, respectively, and 634 (0.058%) and 878 (0.069%) for 
DOR, respectively; this is well within 1% of the ranked database and reflects very high predicted 
binding affinities. Interestingly, neither the Top or Top9 strategies produced interactions between 
the conserved aspartates (MOR: Asp147, DOR: Asp128) and compound 14a (Figure 5.9). 
However, it should be noted that compound 14a is 521 Da, a tad larger than the 500 Da threshold 
from the druglike subset of ZINC. Given the previous observation of a slight dependence of the 
docking score on the molecular weight (Figure 5.6), the use of compound 14a as a positive control 
is called into question. Regardless, the usage of a larger active dataset, such as DUD-E, for model 
validation appears to be more reliable as a control, given the degree of uncertainty exhibited by 
virtual screening methods; the performance of a single compound should not hold sway over an 
entire virtual screening campaign. Though compound 14a performed well in the current pipeline, 
it could potentially have failed with other strategies. Useful information could be gained from the 
inclusion of such a control, but careful consideration should be applied so that erroneous 
conclusions would not be met. 
 
 
Figure 5.8 – Example of Clustering Results for Top9 Strategy. Shown here is the substructure (top) for one cluster that 
represents the four ZINC compounds (bottom). Docking scores are given as the average between MOR and DOR. 
ZINC02131167 selected from this cluster because it had the most favorable score. MarvinSketch was used for drawing 
and displaying the chemical structures, MarvinSketch 18.10.0, 2018, ChemAxon (http://www.chemaxon.com). 
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4. Conclusion 
In the present study, a virtual screening pipeline consisting of sequential ligand- (MAGELLAN) 
and structure-based (AutoDock Vina) methods was developed to predict bifunctional MOR agonist 
/ DOR antagonist compounds. Benchmarking of MAGELLAN in retrospective virtual screening 
using the GPCR-Bench data set confirmed that ligand-based methods work well to retrieve active 
compounds when the known ligands are used in the model. Using the structures of both active 
MOR and inactive DOR, the crystallographic ligands were successfully redocked into the 
respective receptors, resulting in RMSD values of less than 2 Å. Furthermore, it was observed that 
docking with AutoDock Vina and ranking the compounds based on its score resulted in poor 
performance for both MOR and DOR in retrospective virtual screening. However, rescoring 
docking poses with DSX and X-Score comparatively improved performance. Overall, X-Score 
provided better discrimination of active compound over decoy and overall improved enrichment 
compared with DSX and was thus chosen for use in the prospective virtual screening pipeline.  
 
Four post-processing strategies were used to refined the selection of compounds for experimental 
validation, which employed different rescoring strategies (Top and Top9), as well manual 
inspection and substructure clustering. This was done in order to ensure chemical diversity and 
structural insight in the selection procedure. A control bifunctional opioid, compound 14a, was 
spiked into the virtual screen and produced in high-ranking results. Overall, 360 compounds were 
Figure 5.9 – Representative Docked Poses of Compound 14a in MOR and DOR using Top9 Strategy. (A.) For MOR, a 
polar interaction was observed between a secondary amine and the hydroxyl group of Tyr148. (B.) For DOR, interactions 
were seen between the hydroxyl of the 2,6-dimethy tyrosine (Dmt) moiety and the secondary amine of the imidazole 
from His301 and between a secondary amine and the hydroxyl group from Tyr109.  
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found to fit the criteria. While the prospective virtual screening pipeline has been established, its 
success rate cannot be determined unless the compounds are experimentally validated. Thus, 
cAMP and β-arrestin assay will be run on a select subset of compounds to determine whether they 
function as opioids.  
 
Among the insights gained from this study, one of the most important was the fact that docking 
scores appear to be biased towards higher molecular weight compounds in general. As larger 
compounds typically make more interactions, the docking score will reflect as such. To remedy 
this, ligand efficiency measures can be introduced. Further retrospective screens will need to be 
run in order to examine whether this type of post-processing would improve the model.  
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CHAPTER 6.  
Conclusions and Future Directions 
 
1. Conclusions 
Altogether, this dissertation had the goal aiming for the construction of a virtual screening pipeline 
from start to finish. The topic of the first half was on GPCR-related database development, 
resulting in GPCR-EXP (structural data) and GLASS1 (pharmacological data). However, the 
second half was concerned with algorithm and virtual screening pipeline development, producing 
MAGELLAN and the virtual screening pipeline for the discovery of bifunctional opioids. 
 
GPCR-EXP was made in response to the dearth of GPCR experimental structure databases that 
had intuitive interfaces and consistent updating. This is not to say that similar resources, such as 
GPCRdb,2 are not useful; they have their place amongst expert users that can benefit the most from 
their wealth of data. However, the lay user in GPCR structure biology would likely be most 
comfortable with an easy-to-use browsing interface for quick searches, which our database fulfills. 
If anything, GPCR-EXP would be considered a complementary resource. Furthermore, an entire 
roster of predicted GPCR structures of human origin were modelled by GPCR-I-TASSER3 and 
provided on the database web server. Regarding GLASS database, it was originally developed to 
compensate for the now-defunct GLIDA,4 which was a GPCR-ligand database that ceased updates 
in 2010. Pharmacological data was scraped from various external chemical databases and unified 
under one roof. As of the time of writing, GLASS contains over 500,000 unique GPCR-ligand 
associations, as opposed to about 39,000 from GLIDA’s last update; this represents an over 12-
fold increase in data. Both databases should impact the GPCR community for either structure- or 
pharmacology-related needs. In particular, GPCR-EXP has pre-processed structures containing 
only the GPCR, where fusion proteins and other associated proteins (i.e. nanobodies, G proteins, 
etc.) were filtered out; these would be convenient for molecular docking studies, saving the user 
the time in editing the PDB file. Furthermore, superposed structures of the same GPCR would be 
greatly useful in examining structural differences between different activation or ligand-bound 
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states. For ligand-based virtual screens, having a repository of pharmacological data in GLASS 
provides the foundations for algorithm development. Studies that have used this data in their 
pipelines include WDL-RF5 and SwissSimilarity.6  
 
The wealth of information in GLASS database paved the way for the development of 
MAGELLAN, a ligand-based virtual screening algorithm. After numerous revisions and 
refurbishments, the present form of MAGELLAN employs five sequence- and structure-based 
alignment algorithms, which gather related GPCR’s. The corresponding ligand sets from these 
were clustered, where the top clusters were used in a ligand profile. In a large-scale retrospective 
virtual screening test against 224 Glass A GPCRs, MAGELLAN was able to achieve a median 
enrichment factor (EF1%) of 14.38, which is substantially higher than that detected using the 
individual GPCR-alignment methods. Furthermore, MAGELLAN was tested on two public virtual 
screening databases (DUD-E7 and GPCR-Bench8) and achieved an average EF of 9.75 and 13.70, 
respectively, which compares favorably with other state-of-the-art docking- and ligand-based 
methods, including AutoDock Vina9 (1.48/3.16), DOCK 610 (2.12/3.47) and PoLi11 (2.2). A case 
study with the motilin receptor, a former orphan receptor, demonstrated its potential application in 
the de-orphanization of orphan GPCR’s.  
 
In the final portion of the dissertation, a combined virtual screening pipeline was developed, 
utilizing the previous works. Ligand- and structure-based methods each have their own set of 
advantages and disadvantages, and combining these together has been shown in various studies to 
compensate for the shortcomings.12 Thus, a sequential virtual screening pipeline was constructed 
and applied to the discovery of novel bifunctional opioids with mu opioid receptor (MOR) agonist 
and delta opioid receptor (DOR) antagonist activity. Retrospective virtual screens against both 
MAGELLAN and AutoDock Vina were established, and both were reported to have over-random 
discrimination between actives and decoys. In particular, the docking-based screening did not 
perform as well as the ligand-based screening, but this was an expected sacrifice to enable the 
discovery of chemically-novel opioids. Furthermore, rescoring of docking results resulted in 
improved enrichment. Following a variety of post-processing procedures, 360 predicted 
bifunctional opioids were selected for potential experimental validation. 
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2. Future Directions 
2.1 Additional Features for GPCR-EXP 
The current form of the database includes superposed GPCR structures only of the same type. For 
example, all 4 structures for the mu opioid receptor have been structurally aligned. However, 
another feature that would be extremely useful for researchers would be the inclusion of the ability 
to align structures of whichever GPCR in which the user has an interest. This would enable 
convenient, custom access to aligned structures, as opposed to having one type provided. 
Additionally, being able to search for ligands using a molecular editor, such as JSME,13 would be 
helpful for those users interested in GPCR ligands.   
 
2.2 Increasing Data for GLASS 
While massive in scale on its own right, there are additional sources of data that could be 
incorporated into GLASS database in order to bolster its content size. PubChem14 has publicly-
available sets of high throughput screening data from 1.25 million assays covering approximately 
10,000 proteins. There is no doubt that this would be a valuable source of information, but sifting 
through, organizing, and cleaning up the data would be no easy feat. Nevertheless, it would greatly 
be worthwhile exploring this source of data for database integration.  
 
2.3 Screening Orphan Receptors with MAGELLAN 
Many orphan GPCR’s have either no known function or endogenous ligand. In these cases, 
MAGELLAN could be applied to virtually screen chemical databases. A chemically-diverse set 
of top-scoring hits could be tested in the lab to check for receptor activation, which could 
potentially lead to further elucidation on function. Additionally, synthetic ligands that were 
experimentally found to bind to the orphan GPCR could be used as a scaffold for further 
investigation into what endogenous ligand it binds.    
 
2.4 Experimental Validation of Predicted Bifunctional Opioids 
As mentioned throughout, the only way to evaluate a virtual screen is to assay a set number of 
carefully-chosen compounds in the lab, which would be subjected to cAMP and β-arrestin assays. 
The former would measure the extent of receptor activation, while the latter would determine how 
much of the unwanted effector protein is being recruited. Both the mu opioid receptor (MOR) and 
123 
 
delta opioid receptor (DOR) would be screened in the hopes to find cAMP production in MOR but 
not DOR. However, inactivity at DOR does not imply antagonist properties. Thus, binding curves 
must be generated with known competitors to establish binding of a compound to both MOR and 
DOR. Collaboration with the Traynor lab is currently underway for the experimental validation of 
a few top-scoring predicted bifunctional opioids. 
 
2.5 Alternative Metrics for Database Ranking in Virtual Screening 
It was observed that there was a slight association of docking score with the molecular weight of 
the compounds during the retrospective virtual screen with the GPCR-Bench dataset. Therefore, 
many of the selected compounds were of higher overall molecular weight. It should be noted that 
they already constrained by Lipinski’s rule of five,15 as no compound was larger than 500 Daltons. 
An alternative way of rescoring compounds is to employ normalization using the ligand efficiency 
(LE) metric.16 A common representation is shown as follows: 
 
𝐿𝐸 =  
𝛥𝐺
# 𝑜𝑓 𝐻𝑒𝑎𝑣𝑦 𝐴𝑡𝑜𝑚𝑠
 
 
A drawback to this calculation is that it does not scale linearly. Thus, modified metrics have been 
developed to account for this, such as fitness quality (FQ).17 The equation is shown as follows: 
 
𝐹𝑄 = 
𝐿𝐸
𝐿𝐸𝑠𝑐𝑎𝑙𝑒𝑑
 
 
where 𝐿𝐸𝑠𝑐𝑎𝑙𝑒𝑑 =  0.0715 +
7.5398
# 𝑜𝑓 𝐻𝑒𝑎𝑣𝑦 𝐴𝑡𝑜𝑚𝑠
+
25.7079
(# 𝑜𝑓 𝐻𝑒𝑎𝑣𝑦 𝐴𝑡𝑜𝑚𝑠)2
+
361.4722
(# 𝑜𝑓 𝐻𝑒𝑎𝑣𝑦 𝐴𝑡𝑜𝑚𝑠)3 
. This 
would be a very useful metric to utilize in order to acquire more compounds with smaller molecular 
weight in the top of the ranked database. 
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